
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB


 6WXG\3URWRFRO
 6WXG\&RGH '5
 9HUVLRQ 
 'DWH $XJXVW 
  
  
  

0DQDJLQJ$VWKPD3DWLHQWVZLWK$0$=(70$1RYHO'LVHDVH0DQDJHPHQW
3ODWIRUP$& OLQLFDO3LORW6WXG\ 

6SRQVRU $VWUD=HQHFD 3KDUPDFHXWLFDOV/3
$XWKRUV 



[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144566] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144567] OF ABBREVIATIONS AND DEFINITION OF TERMS  ............................  6 
RESPONSIBLE PARTIES  ................................ ................................ ......................  7 
PROTOCOL SYNOPSIS  ................................ ................................ .........................  8 
AMENDMENT HISTORY  ................................ ................................ ...................  13 
MILESTONES  ................................ ................................ ................................ ....... 14 
1. BACKGROUND AND RATIONALE  ................................ ................................ .. 15 
1.1 Background  ................................ ................................ ................................ ............  15 
1.2 Rationale  ................................ ................................ ................................ ................  15 
2. OBJECTIVES AND HYPOTHESES  ................................ ................................ .... 15 
2.1 Primary Objective(s) and Hypothesis(es)  ................................ ..............................  15 
2.2 Secondary Objective(s) and Hypothesis(es) (Optional) ................................ .........  16 
2.3 Exploratory Objective(s) and Hypothesis(es) (Optional)  ................................ ...... 16 
3. METHODOLOGY  ................................ ................................ ................................  16 
3.1 Study Design â€“ General Aspects  ................................ ................................ ............  16 
3.1.1  Data Source(s)  ................................ ................................ ................................ ........  18 
3.2 Study Population  ................................ ................................ ................................ .... 18 
3.3 Inclusion Criteria  ................................ ................................ ................................ ... 18 
3.4 Exclusion Criteria  ................................ ................................ ................................ .. 19 
4. VARIABLES AND EPI[INVESTIGATOR_342393]  ........................  19 
4.1 Exposures  ................................ ................................ ................................ ...............  19 
4.1.1  Patient -Completed  ................................ ................................ ................................ .. 21 
[IP_ADDRESS]  AMAZETM Patient App  ................................ ................................ .........................  21 
[IP_ADDRESS]  Patient Demographic Questionnaire  ................................ ................................ ...... 21 
[IP_ADDRESS]  Patient User Experience Survey  ................................ ................................ .............  21 
[IP_ADDRESS]  Patient Visit Experience Survey  ................................ ................................ ............  21 
[IP_ADDRESS]  System Usability Scale  ................................ ................................ ..........................  22 
[IP_ADDRESS]  PSQ-18 ................................ ................................ ................................ ...................  22 
[IP_ADDRESS]  Follow -up Process Interviews with Patients  ................................ ..........................  22 
4.1.2  MGH Completed  ................................ ................................ ................................ .... 23 
[IP_ADDRESS]  Clinical Case Report Form  ................................ ................................ .....................  23 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144568] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 3 
 [IP_ADDRESS]  Chart Review Case Report Form  ................................ ................................ ...........  23 
[IP_ADDRESS]  System Usability Scale  ................................ ................................ ..........................  23 
[IP_ADDRESS]  Post-study Survey  ................................ ................................ ................................ .. 23 
4.2 Outcomes  ................................ ................................ ................................ ...............  23 
4.2.1  Primary Outcome  ................................ ................................ ................................ ... 23 
4.2.2  Secondary Outcome  ................................ ................................ ...............................  24 
4.2.3  Exploratory Outcome One  ................................ ................................ .....................  24 
4.2.4  Exploratory Outcome Two ................................ ................................ .....................  24 
4.3 Other Variables and Covariates  ................................ ................................ .............  24 
5. STATISTICAL ANALYSIS PLAN  ................................ ................................ ...... 25 
5.1 Statistical Methods: General Aspects  ................................ ................................ .... 25 
5.1.1  Primary Objective: To generate evidence on the feasibility, usability, 
perceived value, and potential benefits of the AMAZEâ„¢ implemented in 
clinical practice  ................................ ................................ ................................ ...... 25 
5.1.2  Second ary Objective(s)  ................................ ................................ ..........................  25 
5.1.3  Exploratory Objective One: To assess how the implementation of AMAZETM 
affects clinical outcomes  ................................ ................................ ........................  25 
5.1.4  Exploratory Objective Two: To identify patients who are most likely to benefit 
from using AMAZETM ................................ ................................ ...........................  [ADDRESS_1144569]  ................................ ................................ ................................ ........  26 
6.1.1  Procedures  ................................ ................................ ................................ ..............  26 
[IP_ADDRESS]  Recruitment  ................................ ................................ ................................ ............  26 
[IP_ADDRESS]  Baseline Visit  ................................ ................................ ................................ .........  27 
[IP_ADDRESS]  Longitudinal Follow -up Interviews and Assessments  ................................ ...........  27 
[IP_ADDRESS]  Cross -Sectional Follow -up Interviews and Assessments  ................................ ...... 28 
[IP_ADDRESS]  Claims Data Ex port ................................ ................................ ................................  28 
6.1.2  Quality Control  ................................ ................................ ................................ ...... 29 
[IP_ADDRESS]  Monitoring  ................................ ................................ ................................ .............  29 
[IP_ADDRESS]  Contacts with the sites to:  ................................ ................................ ......................  29 
[IP_ADDRESS]  Remote Monitoring activities for:  ................................ ................................ ..........  29 
[IP_ADDRESS]  Training of Study Site Personnel  ................................ ................................ ...........  30 
[IP_ADDRESS]  ePRO Programming and Hosting  ................................ ................................ ...........  30 
6.2 Protection of Human Subjects ................................ ................................ ................  30 
6.2.1  Informed Consent  ................................ ................................ ................................ ... 31 
6.2.2  Confidentiality of Study/Patient Data  ................................ ................................ .... 31 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144570] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 4 
 6.3 Collection and Reporting of Adverse Events/Adverse Drug Reac tions  ................  [ADDRESS_1144571] -STUDY SURVEY (FOR HCPS)  ................................ ........  97 
17. APPENDIX  J. PATIENT SATISFACTION QUESTIONNAIRE -18 (PSQ -18) 101 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144572] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 5 
 18. APPENDIX K. SIX -MONTH CHART REVIEW CASE REPORT FORM  ...... 104 
20. APPENDIX L. MGH WORKFLOW FOR IMPLEME NTATION OF DMP IN 
CLINICAL PRACTICE  ................................ ................................ .......................  108 
21. APPENDIX M. PATIENT USER EXPERIENCE SURVEY  .............................  110 
22. APPENDIX N.1 SYSTEM [LOCATION_003]BILITY SCALE (SUS) ADMI NISTERED 
AT MONTHS 1 AND 6: Patients  ................................ ................................ ........  114 
23. APPENDIX N.2 SYSTEM [LOCATION_003]BILITY SCALE (SUS) ADMINISTERED 
AT MONTHS 1 AND 6: MGH Staff  ................................ ................................ .. 115 
24. APPENDIX O. FOLLOW -UP SEMI -STRUCTURED INTERVIEW GUIDES  116 
25. APPENDIX P. RECRUITMENT TRACKING LOG  ................................ .........  124 
26. SIGNATURES  ................................ ................................ ................................ ..... 126 
 
  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144573] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144574]â„¢  Asthma Control Test  
AE Adverse event 
AZ [COMPANY_008]  
CFR  Code of Federal Regulations  
COPD  Chronic obstructive pulmonary disease  
CRF  Case report form  
CRO  Clinical research organization  
DES  Data entry site  
EMR  Electronic  medical record  
ePRO  Electronic patient -reported outcome  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
HCP  Healthcare practitioner  
HIPAA  Health Insurance Portability and Accountability Act  
ICH International Council for Harmonization  
ICS Inhaled corticosteroid  
ID Identifier  
IEC Independent Ethics Committee  
IRB Institutional review board  
LABA  Long -acting beta agonist  
MC Marketing company  
MEOR  Medical Evidence and Observational Research  
MGH  [LOCATION_005] General Hospi[INVESTIGATOR_825426]  
 
 
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
5([ZIP_CODE],%/(3$57,(6
1DPH 3URIHVVLRQDO7LWOH 5ROHLQ
6WXG\$IILOLDWLRQ (PDLO$GGUHVV
 
86
5HVSLUDWRU\0HGLFDO 7HDP/HDG$VWUD=HQHFD 

 0HGLFDO/HDG $VWUD=HQHFD 
 3DWLHQW&HQWHUHG
5HVHDUFK6HQLRU$GYLVRU (YLGHUD 
(OL]DEHWK
%DFFL5HVHDUFK6FLHQWLVW 3ULQFLSDO
,QYHVWLJDWRU(YLGHUD 



6LWH
,QYHVWLJDWRU0*+ 

3XOPRQDU\DQG&ULWLFDO
&DUH0HGLFLQH 6LWH
,QYHVWLJDWRU0*+ 

3HGLDWULF
3XOPRQDU\8QLW 6LWH
,QYHVWLJDWRU0*+ 
 +HDOWK
,QIRUPDWLRQ
7HFKQRORJ\ 3URGXFWLRQ
7HDP/HDG$VWUD=HQHFD 

[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144575] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 8 
 PROTOCOL SYNOPSIS  
 
AMAZETM Asthma Implementation Clinical Pi[INVESTIGATOR_16116] : MGH  
 
 
Backgroun d/Rationale:  [COMPANY_008] (AZ) has developed the AMAZETM disease management 
platform to be used across multiple disease indications to provide a unified experience for the 
management of patients throughout their patient care journey. AMAZETM integrate s multiple 
systems, including a pati ent Application where patients can enter  daily  symptoms  and impact  to 
communicate this information to their healthcare provider ( HCP ), as well as access disease 
educational materials.  Both the patient Application and a clinician dashboard  are integrated with 
the patientâ€™s electronic medical records ( EMR ) to provide a clear view of the patientâ€™s health 
status  both in and out of the clinic. Implementation of AMAZETM within clinical practice  has not  
yet been evaluated . The results from this study will be used to inform any changes or 
modifications that need to be made to the technology platform, its implementation process , and 
explore impact on clinical outcomes . 
Objectives  and Hypotheses : 
The primary study objective is to generate evidence as to the feasibility, usability, perceived 
value, and potential benefits of implementing the  AMAZETM platform  into clinical practice. This 
objective will be accomplished through the generation of evidenc e in two key outcome types:  
1. Technology Outcomes : Key questions to be asked regarding the technology outcomes 
are:  
â€¢ How much is the platform utilized, and what is the perceived value by [CONTACT_825455]?  
â€¢ How user friendly is the platfo rm?  
â€¢ Are staff comfortable with the display and type of data shown?   
â€¢ Which features are/are not useful to patients and clinicians?   
â€¢ Which features need removed or improved upon?   
â€¢ What , if any , bugs are encountered?   
â€¢ How accessible is the app/portal?  
â€¢ What is the optimal frequency of completing the patient log that is achievable and 
meaningful for asthma management?  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144576] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 9 
 2. Process outcomes : How does the implementation of AMAZETM affect clinical 
process? For example, is patien t communication improved, or is there an increase or 
decrease in time spent with patients?  
The exploratory objective s are: 
1. Clinical outcomes : How does the implementation of AMAZETM affect clinical 
outcomes? For example, is there an increase or decrease in utilization of patient 
services, emergency department visits, or clinician contacts?  
2. To identify wh ich segments of patients are most likely to benefit from using 
AMAZETM. 
Since this study is exploratory  regarding the feasibility, usability, and perceived benefit of using 
an electronic platform for disease management , there is no hypothesis testing.  
Methods:  
Study design:  This is a longitudinal  study in which the process of integrating the 
AMAZETM disease management platform  (DMP)  into clinical p ractice will be assessed by 
[CONTACT_825456] .  
For the clinical pi[INVESTIGATOR_27041], patients with asthma of varying severity will be recruited . A 
target of up to 50 total patients  will be recruited and consented for the purposes of the 
clinical pi[INVESTIGATOR_799] , consisting of approximately 33 young adult  (18-35 years old)  and up 
to 17 adult patients  (36 years of age and older) . Approximate r ecruitment targets for the 
study includ e a subset of patients who are new to the practice (less than 3 -month history 
with the practice) and with uncontrolled asthma  (n = approx. 10) as well as patients 
experiencing at least 1 exacerbation in previous 12 months (n=approx. 40).  Exacerbations 
are defined as a change in asthma symptoms requiring a course of oral steroids or steroid 
injection and/or a hospi[INVESTIGATOR_825427].  MGH staff 
responsible for recruiting patients will participate in a training prior to recruitm ent starting , 
including the workflow for steps for the clinical pi[INVESTIGATOR_2268].  
After collecting electronic informed  consent  via Research Electronic Data Capture 
(RED Cap), participants will be instructed to download the AMAZETM application 
software (app) to record their daily  asthma symptoms  and access education al materials  and 
other features of the app. Participants will be allowed to retroactively complete their daily 
asthma symptoms log for up to 7 days prior to the current date. All entries will be date and 
time stamped to track entries. After download ing the app , participants  will be emailed a 
sociodemographic for m to complete. If the participant enable s reminder notifications 
within the app, they will be sent one notification a day at their preferred time if they do not 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144577] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144578] ( ACT â„¢). Importantly, participant responses to the app will be 
monitored  twice daily  by a clinical and research team and alerts may be sent to their 
physician based on responses (e.g. participant reports of ED visits, multiple â€œbadâ€ day 
reports, etc.) via the AMAZETM interface to facilitate communication and to guide 
treatment . 
A random selection of up to [ADDRESS_1144579] team. During the follow -up longitudinal  and cross -sectional 
interviews, participants will be asked questions reg arding their use of the app/platform  and 
what features may need improvements or are particularly of value . 
Additionally , all participants will be asked to complete a patient user experience survey  at 
study months 1, 3, and 6 , as well as  the S ystem Usability Scale (SUS) at study months 
1and 6. All electronic surveys sent outside the app will be sent through REDCap. Clinical 
staff research participants will be asked to complete the SUS at study months one and six. 
Lastly , any time a participant attends a clinic visit (in -person or telehealth), they will be 
emailed a link to complete a patient visit exp erience satisfaction survey. At the end of the 
study, HCPs will be asked to complete a post -study survey via emailed link , while patients 
will be asked to complete the Patient Satisfaction Questionnaire ( PSQ-18).  
Study Sites:   MGH  outpatient adult and ped iatric pulmonary clinics will be implementing 
the clinical pi[INVESTIGATOR_799] .  
Data  Source (s): MGH was selected to implement AMAZETM into their clinical practice  
based on the principal investigator sâ€™ experience and qualifications, the number of asthma 
patients treated in  the clinic, the diversity of the asthma patients treated by [CONTACT_3652], the 
ability of the site to complete the study tasks in the allotted timeframe, and the anticipated 
unique comp onent of clinical pi[INVESTIGATOR_825428].  
Study Population:  Clinic staff will invite eligible patients age >18 years with a  diagnosis 
of asthma to enrol l in the study . Up to 50 patients will be enrolled, including 
approximately 33 young adults (18 -35 years old) and up to 17 adults (36 years of age and 
older) .  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144580] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 11 
 Exposure (s): 
Participants will complete the following measures at differing timepoints:  
â€¢ AMAZETM Patient App, including  a daily symptom log, daily medications, 
healthcare resource utilization (HCRU), ACTâ„¢ completed every month , and 
educational resources   
â€¢ Demographic characteristics questionnaire  
â€¢ Patient User Experience Survey  
â€¢ Patient Visit Experience Survey  
â€¢ SUS 
â€¢ Qualitative Semi -structured Interviews  
â€¢ PSQ-18   
MGH personnel will complete the following measures:  
â€¢ Screening script for patient recruitment (CRC)  
â€¢ Clinical Case Report Form  (CRF)  (CRC)  
â€¢ Chart Review CRF  (CRC)  
â€¢ SUS (Clinical staff)  
â€¢ Post-Study Survey (Clinical staff)  
Outcome (s): 
â€¢ Onboarding process evaluation  
â€¢ Product attributes  
â€¢ Patient visit and user experience  
â€¢ Clinical staff experience  
â€¢ Clinical process assessment  
â€¢ SUS scores  
â€¢ PSQ-18 score s 
â€¢ Post-study survey responses  
â€¢ Qualitative interview responses  
 
Sample Size Estimations:  As the aim of this study is to assess the process and feasibility of 
implementing AMAZE â„¢, inferential statistics will not be performed , and a formal sample size 
estimation is not applicable. MGH  will target up to 50 patients . Implementing AMAZE â„¢ among 
up to 50 patients  will provide MGH  with enough  experience to provide feedback on the outcomes, 
barriers, benefits, challenges, ease of implementation , and areas for improvement for future 
integration as a platform.  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144581] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 12 
 Statistical Analysis : Descriptive statistics (n, frequency, mean, and standard deviatio n [SD]) will 
be used to characteri ze the sample in terms of sociodemographic and clinical characteristics. The 
sociodemographic and clinical characteristics will be summarized for the sample overall as well 
as for each site. Descriptive statistics (n, freq uency, mean, and SD) will also be used to 
summarize the results from the patientsâ€™ frequency of use of the daily log and educational 
resources, ACT â„¢ scores, responses to the Patient Visit Experience Survey , the SUS, and the 
results of the patient PSQ-[ADDRESS_1144582] -study survey .  
Qualitative interviews  will be summarized based on interviewersâ€™ notes  using a detailed 
interviewer matrix . The interviews will be audio recorded , and transcribed by a third -party vend or 
(TransPerfect) , should the audio need to be reviewed to summarize findings. The interview results 
will be summarized in tabular format, with key recommendations, advantages, and disadvantages 
grouped. Specifically, barriers, benefits, challenges, ease o f implementation, and areas for 
improvement  will be summarized .  
Safety Handling Plan:  A Safety Handling Plan  has not been  developed for this study.  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144583] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 13 
 AMENDMENT HISTORY  
Date  Section of study protocol  Amendment or update  Reason  
  N/A  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144584] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144585] Participant in Q2 2021  
Database Lock  Q4 2021  
High Level Results in Tabular Format  Q4 2021  
Final Report  Q1 2022  
 
 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144586] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 15 
 1. BACKGROUND AND RATIONALE  
1.1 Background  
Uncontrolled and severe uncontrolled asthma (SUA) are common disorders that are often difficult 
to identify and manage.  The clinical and economic burden of SUA is disproportionately high, 
accounting for nearly 40% of asthma -related costs1,2 and uncontrolled asthma affects over 50% of 
children and adults with asthma. With advances in asthma therapi[INVESTIGATOR_014], an urgent need exi sts to 
optimize  uncontrolled and SUA recognition and clinical  management . 
1.[ADDRESS_1144587] to a suboptimal level of control. This can result in frequent exposu re to systemic steroids  
along with frequent  urgent care/ER visits and hospi[INVESTIGATOR_165433]. The AMAZETM platform aims to 
address this clinical need through better communication between patients and their clinical teams 
regarding the patientsâ€™ level of asthma control with the ultimate goal of  improvement asthma 
management and improved health outcomes.  This study aims to test the feasibility of 
implementing AMAZETM in a specialist clinical practice to manage asthma.  
2. OBJECTIVES AND HYPOTHESES  
2.1 Primary Objective(s) and Hypothesis(es)  
The primary study objective is to generate evidence on the feasibility, usability, perceived value, 
and potential benefits of the AMAZETM disease management platform implemented in clinical 
practice. Since this is an exploratory study involving a mobile ap p and DMP , there is no 
hypothesis testing. The primary objective will be assessed through the following key outcomes:  
1. Technology Outcomes:  Key questions to be asked regarding the technology outcomes 
are: 
â€¢ How much  is the platform utili zed, and what is the perceived value by [CONTACT_825455]?  
â€¢ How user friendly is the platform?  
â€¢ Are staff comfortable with the display and type of data shown?   
â€¢ Which features are / are not useful to patients and clinicians?   
â€¢ Which featu res need removed or improved upon?   
â€¢ What if , any bugs , are encountered?   
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144588] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 16 
 â€¢ How accessible is the app/portal?  
â€¢ What is the optimal frequency of completing the patient log that is achievable and 
meaningful for asthma management?  
2. Process outcomes:  How does th e implementation of AMAZETM affect clinical process? 
For example, is patient communication improved, or is there an increase or decrease in 
time spent with patients?  
2.2 Secondary Objective(s) and Hypothesis(es) (Optional)  
There are no secondary objectives for  this study.  
2.3 Exploratory Objective(s) and Hypothesis(es) (Optional)  
There are two exploratory objectives for this study.  
1. Clinical outcomes:  How does the implementation of AMAZETM affect clinical 
outcomes? For example, is there an increase or decrease in utili zation of patient 
services, emergency department visits, or clinician contacts?  
2. To identify segments of patients that are most likely to benefit from using AMAZETM. 
3. METHODOLO GY 
3.1 Study Design  â€“ General Aspects  
This is an implementation study to assess the feasibility, usability, perceived value, and potential 
benefits of integrating the AMAZETM DMP  at MGH . The AMAZETM platform (developed by 
[CONTACT_38227] /BrightInsight) consists of a clinician dashboard to guide treatment and asthma 
management, and a patient application to enter daily symptoms and medications that can trigger 
alerts to the clinician dashboard. For this implementation study, the sites will b e trained on the use 
of the AMAZETM platform and will launch the program in the target patient population.  
For clinical pi[INVESTIGATOR_825429], MGH  will recruit up to 50 patients with asthma , including 
approximately 33 young adults (18 â€“35 years old) and up to 17 adults . Approximately 10 new  
patients to the practice (less than 3 -month history with the practice) but with uncontrolled asthma  
will be recruited , along with  approximately  [ADDRESS_1144589] one exacerbation per 
year. Eligible participants will be invited to participate in the study either in person or via 
telephone or Zoom call using a standardi zed recruitment script ( Appendix A ). Alternatively, a 
recruitment email will be  first sent from a physician with a flyer attached to introduce the app and 
the study to participants ( Appendix C ). A follow -up Zoom video conversation can also be 
scheduled with the participants. If interested  in participating in the study , they will provide their 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144590] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 17 
 email address to the site staff so that a consent form can be sent to them via  email ( Appendix B ) 
to sign via REDCap. The MGH  staff will confirm the email address provided by [CONTACT_825457].  If the email address differs, 
the staff will modify the dashboard to the correct email. The email address collected duri ng the 
screening visit  will be used for emailing the surveys throughout the study.  The MGH  staff will 
review the consent  with the patient either in person or via telephone or Zoom call and answer any 
questions they may have.  
After consenting to participat e, patients will be sent an introductory email  (Appendix D) with link 
to download the app (Appendix  E), and register as a patient with a unique identifier ( ID). Once 
the app has been downloaded , the patient will be asked to creat e their unique ID . Within the app, 
participants will be provided with access to all education al materials and asked to complete the 
daily symptom log. The MGH  research staff will complete a clinical case report form (CRF; 
Appendix F) to record baseline clinical information about the patient , while  participants  will be 
asked to complete a sociodemographic form ( Appendix G) via an emailed link. If the participant 
enable s reminder notifications within the app, they will be sent one notification a day at their 
preferred time if they do not complete the app daily.   BreezoMeter, a third -party air quality 
vendor, will be assisting in the tracking and alerting of the air qualit y in the participantâ€™s location 
if the location setting is turned on.  
After study launch, Evidera will conduct qualitative , longitudinal,  follow -up interviews regarding 
process impl ementation with a random selection of patient participants (approximately 1 out of 5) 
at study months one, three, and six  to gain a deeper understanding of the feasibility of 
implementing the asthma AMAZETM platform.  Prior to launching the interviews, approximately 
12 patient participants will be randomly selected to participate in the qualitative interviews at 
study months one, three, and six to understand the feasibility and usability of the patient app over 
time, the perceived benefit (e.g., if there is an increase in the patientâ€™s abili ty to interact with their 
physician, if it enhances speed and/or quality of response, etc.), and how it can be improved.  In 
addition to the longitudinal interviews, a one -time, cross -sectional interview may be conducted by 
[CONTACT_825458]  2, 4, and 5 with a random selection of up to 5 patient 
participants at each timepoint (excluding the up to 12 participants who will be participating in the 
longitudinal interviews). The cross -sectional interviews are meant to help capture any new 
features  or feedback from participants during the off -months in the longitudinal interviews and 
will be conducted on an as -needed basis.   
In addition to the qualitative interviews, patient participants will be emailed a link to complete an 
electronic patient visi t experience survey (Appendix H ) after attending an in -person or telehealth 
visit with their doctor to evaluate their overall satisfaction  with AMAZETM and its impact on the 
visit. Evidera will receive a data report from BrightInsight with participant BrightInsight ID, date 
of visit, and status of visit completion . Evidera will then share  the IDs with MGH to generate a 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144591] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144592] 
with the app longitudinally throughout the study . At the  end of the study (approximately 3 months 
after completion of enrollment)  prescribing providers  and study coordinators  at MGH  will 
complete a Post-study Survey  (Appendix I) and patient participants will complete the PSQ -18 
(Appendix J). The focus of these questionnaire s will be to obtain additional feedback on the 
implementation of AMAZE â„¢ and participant satisfaction with the medical care they receive, 
respectively . All electronic surveys sent outside the app will be sent through REDCap . At study 
month Six, MGH staff  will also be asked to complete a chart review  CRF  (Appe ndix K ) for each 
patient. The patient app and/or clinician dashboard may be revised throughout the clinical pi[INVESTIGATOR_825430].  
3.1.1 Data Source (s) 
Participants will be recruited from MGH . MGH  will recruit approximately 33 young adults (18 â€“
35 years old) and up to 17 adults for a total sample of up to 50 patients . In addition, MGH  will 
aim to recruit patients who are new to the practice (less than 3 -month history with the practice) 
but with uncontrolled asthma (n= approx. 10) and patients experiencing at least 1 exacerbation in 
previous 12 months (n=approx. 40) .  
3.2 Study Population  
Clinic staff will invite patients age >[ADDRESS_1144593] meet all the following criteria to be considered for enrol lment:  
1. >18 years of age at the time of enrollment  
2. Clinically confirmed d iagnosis of asthma  (with or without COPD)  
3. Access to a smartphone with  internet access with the following requirements: iOS 
(Operating System iOS 13 or newer and Devices iPhone 8 or newer)  or Android 
(Operating System 8.0 or newer)  
4. Able to understand and speak English sufficiently to be able to use the AMAZE â„¢ patient 
app 
5. Willingness to participate in a telephone interview and be audio -recorded  
6. Consenting to participate in the study  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144594] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 19 
 3.4 Exclusion  Criteria  
Patients meeting any of the following criteria will not be included in the study:  
1. No current diagnosis of asthma  
2. Has a cognitive impairment, hearing difficulty, acute psychopathology, medical condition, 
or insufficient knowledge of the English language that, in the opi[INVESTIGATOR_871], 
would interfere with his or her ability to agree to participate and/or com plete the ACT â„¢. 
4. VARIABLES AND EPI[INVESTIGATOR_342393]  
4.[ADDRESS_1144595] and confirm eligibility. For the clinical 
study launch, a standardi zed screening script ( Appendix A ) will be used that provides an overview 
as to the purpose and nature of the implementation study , as well as a description of the potential 
to participate in  the longitudinal or one -time follow -up interviews  (if randomly selected to 
participate) .   
The timing of each key procedure/exposure, and the responsible party for each procedure is 
depi[INVESTIGATOR_203659] 1. Following the baseline visit, Ev idera will randomly select up to 12 
patient participants for longitudinal interviews, as well as up to 5 participants per timepoint to 
take part in cross -sectional interviews. A detailed workflow of the implementation of the DMP in 
MGH clinical practice is  included in Appendix L.  
Table 1. Schedule of Study Assessments  
Procedures  Baseline  Month 
One Month 
Two  Month 
Three  Month 
Four  Month 
Five Month 
Six 
Screen and Recruit1 M       
Consent via RedCap  for 
Participants  M/P       
Download App  P       
Completion of App  P P P P P P P 
Monitor Clinician 
Dashboard  M M M M M M M 
Clinical CRF  M       
Sociodemographic Form  P       
Patient User Experience 
Survey   P  P   P 
System Usability Scale   P/M     P/M 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144596] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 20 
 Procedures  Baseline  Month 
One Month 
Two  Month 
Three  Month 
Four  Month 
Five Month 
Six 
Patient Visit Experience 
Survey2  P P P P P P 
Participant Longitudinal 
Follow -up Interviews 
(n=approx. 12 )  P/E  P/E   P/E 
Participant Cross -sectional 
Follow -up Interviews (n=  
approx. 5 )   P/AZ   P/AZ  P/AZ   
Consent for MGH staff 
participating in  surveys   M      
Patient Satisfaction 
Questionnaire -[ADDRESS_1144597] -Study 
Survey        M 
Chart Review CRF        M 
1MGH will recruit approximately  50 patients for the clinical pi[INVESTIGATOR_799] . Any additional patients invited to use the app 
beyond the maximum sample size will not be included in any analyses.  
2The Patient Visit Experience Survey will be sent after a confirmed visit with their HCP at the site following baseline 
visit.  
Abbreviation: AZ=[COMPANY_008] DMP Product Team; CRF = case report form; E=Evidera; M=MGH; P=Participant  
Patient p articipants will be compensated $10 after completion of applicable surv eys from baseline 
through month 6.  In addition, if a participant is randomly selected for an interview, they will also 
be compensated $75 per interview completed.  Patient participants will be randomized into one of 
three groups , and will only complete one of these groups:  
1. Longitudinal (three total) interviews and receive up to $265  
2. Cross -sectional (one -time) interview and receive up to $115  
3. Not randomized to be interviewed and receive up to $40  
 
Below is a table outlining the remuneration payment schedule  for patient participants .   
Table 2. Remuneration Payment Schedule for Patient Participants  
Procedures  Baseline  Month One  Month Three  Month Six  
Completion of Electronic Surveys  $10 $10 $10 $10 
Completion of Interview  
(if randomly selected )  $75 $75 $75 
Total Possible Remuneration  $10 $85 $85 $85 
 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144598] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 21 
 4.1.1 Patient -Completed  
[IP_ADDRESS]  AMAZETM Patient App  
At the initial baseline visit, participants will be asked to download the AMAZETM app (Appendix 
D). The patient app includes a daily log of asthma symptoms, as well as additional questions on 
their asthma experience. As a part of the app, patients will have access to educational resources 
about their ast hma and asthma medication. The resources are meant to be informative in nature 
based on how the participant responds to questions in their daily log. The app allows participants 
to communicate with the MGH  staff as well as see daily and weekly trends in th eir asthma. My 
plan, a component within the app, contains medications, air quality and information regarding 
upcoming appointments.  
Every four weeks, the ACTâ„¢ will also be administered and completed by [CONTACT_2299] .[ADDRESS_1144599]â„¢ consists of five items with the total score used to identify participants with poor asthma 
control. The ACTTM classifies well controlled as â‰¥20, not well controlled as 16 â€“19, and very 
poorly controlled as â‰¤15. The ACTâ„¢  questions with a four-week recall period address medication 
use, asthma symptoms and asthma -relate d impairment. The English version will be used in this 
study only.  
[IP_ADDRESS]  Patient Demographic Questionnaire   
Participants will complete a brief self -administered Patient Demographic Questionnaire 
(Appendix G) following download of the patient application  and providing their informed consent 
to participate; this questionnaire will be sent to all participating patients via  an email  link. This 
form collects the partic ipantâ€™s age, ethnicity, living situation, employment, and education, and 
will be used to describe the sample and assist with interpreting the results.   
[IP_ADDRESS]  Patient User Experience Survey  
All participants who consent to participate in the full clinical study w ill be emailed at months 1, 3, 
and 6 the patient user experience survey ( Appendix M). The survey is meant to allow participants 
the opportunity to provide feedback on a monthly basis as they continue to interact with the app. 
The survey results will be reviewed  to identify if any changes to the app are needed.  
[IP_ADDRESS]  Patient Visit Experience S urvey  
The patient visit experience survey (Appendix H) will be sent electronically any time a participant 
attends an in-person or telehealth clinic visit. Bright Insights will generate weekly reports to 
provide Evide ra with IDs for those who completed clinic visits. Evidera will subsequently notify 
the electronic survey vendor to send  the survey via  email. This survey will evaluate patient 
satisfaction with their visit and any benefits the App provided for the visit.     
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144600] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 22 
 [IP_ADDRESS]  System Usability Scale  
The System Usability Scale (SUS) (Appendix  N.1) will be sent electronically at months one and 
six for participants to provide feedback on the AMAZE patient app. The SUS has been valid ated 
in previous usability studies to quantitatively evaluate the usability of a system, including mobile 
apps.4  
[IP_ADDRESS]  PSQ -18 
At the end of the clinical pi[INVESTIGATOR_799] (approximately 6 months), all participants who consented and 
participated in the clinical pi[INVESTIGATOR_825431] a link to the Patient Satisfaction 
Questionnaire -18 (PSQ -18; Appendix J).5 The PSQ -18 is a generic measure used to assess 
patientâ€™s overall satisfaction with their medical care and interactions with their HCPs. A higher 
score indicates greater satisfaction.  
[IP_ADDRESS]  Follow -up Process Interviews  with Patients   
Longitudinal Interviews  
A semi-structured interview guide ( Appendix O) will be used to obtain information from a 
randomly selected subset of patients at months one, three , and six during longitudinal, follow -up 
interviews to gain a deeper understanding of the feasibility of implementing the AMAZEâ„¢ 
platform. The semi -structured interview guides will include an intro duction and follow with 
specific questions and probes designed to facilitate discussion and optimize  consistency across 
interviews. The interview guide will elicit recommendations for improving the AMAZE platform 
experience for patients . Additional unscrip ted probes may also be used to gain further information 
or clarification. The interview guides may be modified as necessary during the study.   
Cross -Sectional Interviews  
Semi -structured interview guides for months 2, 4, and 5 (Appendix O) may be used to obtain 
information from a randomly selected subset of patients at months 2, 4, and [ADDRESS_1144601] team  to gain a deeper understanding of the 
usability of the AMAZEâ„¢ platform. The interviews will be conducted as needed. The interviews 
are meant to be briefly provide feedback on any new roll outs or issues with the app that cannot be 
captured during the long itudinal interviews. The semi -structured interview guides will include an 
introduction and follow with specific questions and probes designed to facilitate discussion and 
optimize  consistency across interviews. The interview guide will elicit recommendatio ns for 
improving the AMAZE platform experience for patients. Additional unscripted probes may also 
be used to gain further information or clarification. The interview guides may be modified as 
necessary during the study.  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144602] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 23 
 4.1.2 MGH  Completed  
[IP_ADDRESS]  Clinical Case Repor t Form  
For each participant, MGH  will complete a paper clinical case report form (CRF; Appendix F) 
during the initial site visit  after informed consent is obtained . The clinical CRF serves to 
characterize patients b ased on their history of asthma, current medications, and the HCPâ€™s rating 
of the patientâ€™s asthma severity and control.  
[IP_ADDRESS]  Chart Review  Case Report Form  
For each participant, MGH  will complete a chart re view clinical CRF ( Appendix K) at month six. 
The follow -up clinical CRF will evaluate exacerbation history during the last 6  months, healthcare 
resource utili zation, change in therapy , and COVID -19 diagnosis.  
[IP_ADDRESS]  System Usability Scale  
The SUS ( Appendix N.2) will be asked verbally to clinical staff during the telephone interviews at 
months one and six to provide feedback on the clinical dashboard.  
[IP_ADDRESS]  Post-study Survey  
All clinical staff who participate will be asked to complete the Post -study Survey ( Appendix I) 
after patient enrollment has completed ( approximately four months after study launch ). The 
purpose of this survey is to obtain feedback on the i mplementation of the AMAZEâ„¢ platform 
within each siteâ€™s medical practice.  
4.2 Outcomes  
4.2.1 Primary Outcome  
To address the primary objective to generate evidence on the feasibility, usability, perceived 
value, and potential benefits of the AMAZEâ„¢ implemented in cli nical practice, the following 
outcomes will be assessed:  
â€¢ Technology Outcomes: Technology outcomes will be assessed in a variety of ways 
throughout the clinical pi[INVESTIGATOR_799]. Usage metrics will be collected  by [CONTACT_825459], and utilizing  the 
educational resources provided . The usage of the clinical dashboard will also be tracked to 
evaluate the utility of the dashboard to  MGH . Usage metrics will be analyzed by [CONTACT_825460].  
o The qualitative interviews from the longitudinal  months one, three , and six 
interviews  as well as the cross -sectional months two, four, and five interviews  will 
provide data regarding the usefulness of the technology from a patient perspective.   
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144603] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 24 
 o The patient user experience surveys may be evaluated as well to determine how the 
platform is being utilized and the user friendliness of the App.  
â€¢ Process Outcomes:  Similar to the technology outcomes described above, process 
outcomes will be evaluated using the patient follow -up interviews, patient visit experience 
survey, PSQ-[ADDRESS_1144604] exploratory  objective to assess how the implementation of AMAZETM affects 
clinical outcomes, the following outcomes will be assessed:  
â€¢ Clinical Outcomes: As part of AMAZETM, all patients will be asked to utili ze the App by 
[CONTACT_825461]. Additionally, s ites will be asked to complete a 
baseline clinical CRF and a six-month chart review CRF for each participant. T he baseline 
clinical CRF will capture information on the patientâ€™s asthma and smoking history as well 
as current asthma medications. The chart review CRF will include questions on recent 
exacerbations, healthcare resource utili zation, change in asthma ther apy, and exposure to 
COVID -19. The variables collected from these CRFs will be used to evaluate how 
AMAZETM impacts key clinical outcomes of interest. Descriptive statistics (n, frequency, 
mean, and SD) will be utili zed. 
4.2.[ADDRESS_1144605] 
likely to benefit from using AMAZETM, information collected from the patient sociodemographic 
form  and clinical CRF  will be used and analyses will be stratified by [CONTACT_336894]/segments. 
The following  patient segments may  be considered:  age cohorts (TBD); sex; asthma severity 
cohorts (TBD); educational cohorts (TBD); and minority cohorts (TBD).  Other patientsâ€™  segments 
may be considered after reviewing sample  distribution.     
4.3 Other Variables and Covariates  
Demographic a nd/or clinical patient data will be used to summari ze the sample overall and by 
[CONTACT_3725]. 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144606] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 25 
 5. STATISTICAL ANALYSIS PLAN  
5.1 Statistical Methods : General Aspects  
Descriptive statistics (n, frequency, mean, and SD) will be used to characteri ze the sample in 
terms of sociodemographic and clinical characteristics. The sociodemographic and clinical 
characteristics will be summari zed for the sample overall as well as for each site . 
5.1.[ADDRESS_1144607] ive: To generate evidence on the feasibility, usability, perceived 
value, and potential benefits of the AMAZEâ„¢ implemented in clinical practice   
The technology outcomes described in section 4.2.1  above will be analy zed both qualitatively and 
quantitatively . The interview ( longitudinal  and cross -sectional follow -up) results will be 
summari zed in tabular format, with key recommendations, advantages, and disadvantages 
grouped. Specifically, barriers, benefits, challenges, ease of implementation, and areas for 
improvement will be summari zed. Results from the patient visit experience survey, month ly 
patient user experience surveys, PSQ-18, post-study survey, and usage metrics provided by 
[CONTACT_825462] (n, frequency, mean and SD).  
The process outcomes described in section 4.2.1  above will be analy zed similar to the technology 
outcomes. The interview results will be summari zed in tabular format; survey results will be 
analy zed using descriptive statistics.  
5.1.2 Secondary Objective(s)  
There are no secondary objectives for th is study.  
5.1.3 Exploratory  Objective  One: To assess how the implementation of AMAZETM 
affects clinical outcomes   
The variables collected from the  baseline Clinical  CRF  and six-month chart review form  will be 
used to evaluate how the AMAZETM patient App impacts key clinical outcomes of interest  (e.g. 
clinician visits, healthcare resource utilization , change in therapy) . Descriptive statistics (n, 
frequency, mean, and SD) will be utilized. 
5.1.4 Exploratory O bjective  Two : To identify patients who are most likely to benefit 
from using AMAZETM  
The variables collected form the patient sociodemographic form and Clinical CRF will be used to 
stratify patients into segments/subgroups. Proposed variables of interest are age, sex, asthma 
severity, educational subgroups, and minority status. Additional variables may also be used in the 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144608] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 26 
 exploratory analyses. Descriptive statistics (n, frequency, mean, and SD) will be used to 
characteri ze patients most likely to benefit from the App across these variables.   
5.[ADDRESS_1144609] access to the appropriate devices will be tracked.  
5.2.2 Adjustment for Multiple Comparisons  
Not Applicable.  
5.2.3 Strengths and Limitations  
The strengths of this study  are that it aims to  include a diverse sample  of patients across MGH . 
The limitations of this study include that MGH  may not be generalizable  to all clinical sites 
treating asthma patients across the US and that the sample of patients may not be generalizable  to 
all asthma patients >18 years of age.  
5.3 Sample Size and Power Calculations  
As the aim of this study is to assess the process and feasibility study of implementing the 
AMAZE â„¢ in clinical practice , inferential statistics will not be conducted,  and a formal sample 
size estimation is not applicable. MGH  will target 50 patients. Implementing the AMAZE â„¢ with 
up to  [ADDRESS_1144610]  
6.1.1 Procedures  
[IP_ADDRESS]  Recruitment  
Participants will be recruited from MGH . MGH  will identify potential participants through 
chart/database/electronic medical record (EMR) reviews. Potentially eligible patients will also be 
identified using the Research Patient Data Registry (RDPR) Scheduled Query feature. We will 
search for patients  diagnosed with asthma with or without COPD . Upon receipt of each updated 
patient list, study staff will perform a chart review of listed patients to confirm eligibility. Once 
patient eligibility is confirmed, study staff will provide the confirmed list to  appropriate clinical 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144611] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 27 
 staff who, at their discretion, will approach their patients regarding participation in the research 
study.  
MGH staff  will approach patients during a regularly scheduled clinic visit or call potentially 
eligible participants and intro duce the study using an introductory script  (Appendix A ). The script 
provides an overview as to the purpose and nature of each study . Alternatively, a recruitment 
email will be first sent from a physician with a fl yer attached to introduce the app and the study to 
participants ( Appendix C ). A follow -up Zoom video conversation can also be scheduled with the 
participants. For the clinical pi[INVESTIGATOR_799], b est efforts will be m ade to recruit approximately 10 
patients who are new to the practice (less than 3 -month history) but with uncontrolled asthma and 
approximately [ADDRESS_1144612] 1 exacerbation in the previous 12 months . In 
addition, over half the sample will be young adults (18 â€“35 years old).  The research staff will 
document patient  interest and the recruitment quota using the Recruitment Tracking Log 
(Appendix P), including documentation of the number of  patients who choose not to participate.   
[IP_ADDRESS]  Baseline Visit   
During the baseline visit , interested participants that have verbally consented to participate will  be 
sent an email ( Appendix B ) by [CONTACT_825463][INVESTIGATOR_799]. The email address will be confirmed during screening and 
staff will add the email address in the dashboard system if it differs from the email address in the 
dashboard. MGH staff  will review the consent  either in person or via telephone and answer any 
questions they may have. O nce the participant and MGH  staff have signed , a fully executed 
version will be available for download. The consent will acknowle dge the random selection of 
patients who will be asked to complete either a longitudinal or cross -sectional follow -up 
interview. After consent, patients will be provided with a link to download the App ( Appendix  E) 
and register as a patient with a unique i dentifier (ID). After completion of the baseline visit , 
patients will be emailed a  brief sociodemographic questionnaire  (Appendix G). MGH will also be 
asked to complete a clinical CRF ( Appendix F) to capture initial clinical characteristics. Patients 
will be remunerated $ 10 for completing the sociodemographic questionnaire at the baseline visit.  
Evide ra will provide  the email addresses collected at the screening visit  to the web survey vendor 
in order to email the follow -up survey  links.  
[IP_ADDRESS]  Longitudinal Follow -up Interviews  and Assessments   
Throughout the study duration, p articipants will be able to access the daily log of symptoms, 
questions on their asthma experience, and educational resources each day they interact with the 
AMAZETM app. Every month, the app will prompt the completion of the ACTTM. Based on the 
responses on the patient App, a notification or alert may be triggered in the clinician dashboard 
for the sites to contact [CONTACT_825464] 
(e.g., complete a clinic visit). In addition to the daily App comp letion, patients will be emailed a  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144613] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 28 
 monthly patient user survey to complete , as well as the SUS at months one and six. Patients will 
be remunerated $ [ADDRESS_1144614]  for completion of 
applicable surveys . In addition, patients who are randomly selected will be compensated $ [ADDRESS_1144615] -party vendor ( TransPerfect) . 
Interviews are expected to last approximately 30 to 45 minutes for patients. Patients will be 
remunerated $ [ADDRESS_1144616] at each interview time point.  
[IP_ADDRESS]  Cross -Sectional Follow -up Interviews and Assessments  
Participants will be asked to complete the patient visit experience survey after attending an in -
person or telehealth visit with their doctor. The survey will be emailed to participants after 
confirmation of  completion of the visit.  
A random selection of up to [ADDRESS_1144617] the participants to schedule the 
cross -sectional interview. To maintain data privacy, a teleconf erence line will be provided to the 
participants and AZ team.  The goal of the one -time interview  will be to evaluate any usability and 
feasibility issues with patients and provide an opportunity for participants to provide feedback on 
areas for growth  or change  in the patient App  that cannot be captured during longitudinal 
interviews . Patient p articipants will be remunerated $ [ADDRESS_1144618] , and 
satisfaction with medical care received, respectively . MGH  staff will also com plete a 6-month 
clinical CRF.  
[IP_ADDRESS]  Claims Data Export  
After the participants consent to participate, Evidera, and AZ will work to export deidentified 
claims data at mont hs 6. The linking of deidentified data with the clinical pi[INVESTIGATOR_825432]-identified data 
will be outlined in detail in a subsequent study amendment prior to month 3. Alternatively, claims 
data may be linked to clinical pi[INVESTIGATOR_91196] . The processes related to  claims linking will be 
revised during an amendment. Any p rocedures related to this will not be implemented until IRB 
approved.   
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144619] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 29 
 6.1.2 Quality Control  
[IP_ADDRESS]  Monitoring  
Before the first subject is recruited into the study, the Medical Evidence and Observational 
Research ( MEOR ) Delivery Director, MEOR Operations Lead or CRO Representative (i.e., 
Evidera) will:  
â€¢ Establish the adequacy of the facilities and the investigatorâ€™s capability to appropriately 
select the sample; and  
â€¢ Discuss with the investigator(s) (and other personnel involved with the study) their 
responsibilities with regards to protocol compliance, and the responsibilities of AZ or its 
representativ es. This will be documented in an Interventional Study Primary Agreement or 
equivalent between A Z/delegate and the investigator.  
During the study the local marketing company ( MC) representative or delegate can implement 
different activities to assure compl iance with AZ standards of quality. These activities could 
include but are not limited to:  
[IP_ADDRESS]  Contacts with the sites to:  
â€¢ Provide information and support to the investigator(s)  
â€¢ Confirm that the research team is complying with the protocol and that data are be ing 
accurately recorded in the CRFs  
â€¢ Ensure that the CRFs are completed properly and with adequate quality  
[IP_ADDRESS]  Remote Monitoring activities for:  
â€¢ Checking informed consent forms (ICF)  
â€¢ Review enrollment forms and subsequent CRFs   
â€¢ Export of claims data  
The extent and nature of monitoring will be decided during the study planning based on design, 
complexity, number of subjects, number of sites, etc.  Interventional Research Center (multi 
country)/MC will give some recommendations that could be  locally adapted.  
Different signals ( e.g., high rejection rate in a site) should be used as potential identification of 
low protocol compliance by [CONTACT_431].  
If these or any other signal occurs or if the CRO  is suspi[INVESTIGATOR_701949] a potential non -optimal lev el of 
protocol compliance by [CONTACT_6962], specific measures should be adopted to evaluate the 
situation, identify the issue and implement specific action plans to correct the situation.  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144620] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 30 
 [IP_ADDRESS]  Training of Study Site Personnel  
Evidera will ensure trainin g of MGH  personnel for the implementation of AMAZETM clinical 
pi[INVESTIGATOR_825433]. MGH  principal investigator s will ensure that 
appropriate training relevant to the study is provided to MGH staff, and that any new information 
relevant to the performance of this study is forwarded to the staff involved.  
[IP_ADDRESS]  ePRO Programming and Hosting  
REDCap will be used for the electronic patient and clinical site staff surveys  and clinical case 
report forms (CRFs) . The survey hosted w ill include the sociodemographic form, monthly patient 
user experience survey, patient visit experience survey, SUS, post -study survey, and PSQ -18. A 
separate HIPAA -compliant vendor, BrightInsight, will host the  data management system to 
collect and monito r data captured by [CONTACT_825465].  
For both vendors, the quality a ssurance process will include extensive end -to-end testing.  During 
all data collection, the survey responses will be tracked by [CONTACT_402326] â€”not 
participant names.  All electronic  surveys will be emailed to patient participants and clinical staff 
research participant through REDCap .  
MGH will export and transfer the CRF and survey data in SAS format to Evidera via MGB 
Secure File Transfer . The CRF and survey data will then be entered into the database and 
reviewed by [CONTACT_825466].  Data discrepancies will be identified and resolved.  
The web survey developed for the patient and MGH  staff surveys will be tested prior to study 
launch.  
6.2 Protection of Human Subjects  
This Interventional Study will be performed in accordance with ethical principles that are 
consistent with the Declaration of Helsinki, ICH GCPs, GPP and the applicable legislation on 
Non-Interventional Studies and/or Interventional Studies.  
The Investigator will perform the  clinical pi[INVESTIGATOR_825434] -how.  
The final protocol of the clinical  pi[INVESTIGATOR_16116], including the final version of the Patient Informed 
Consent Form, must be approved or given a favourable opi[INVESTIGATOR_825435]/Institutional Review Board (IRB)/Independent Ethics Committee (IEC).  
The Ethics Committee/IRB/ IEC must also approve any amendment to the protocol and all 
advertising used to recruit subjects for the study, according to local regulations.  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144621] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 31 
 6.2.1 Informed Consent  
MGH  staff will be responsible for ensuring that each participant (patients and MGH staff) fully 
understands the studyâ€™s nature, purpose, procedures, risks, and benefits. For those patients and 
MGH staff taking part in the clinical pi[INVESTIGATOR_825436], electronic consent will be presented to them via 
REDCap. At the screening, the MGH  staff will confirm the email address to send the REDCap 
document to and update the dashboard as needed with any patient email addresses that are not in 
the system. Evidera will provide the email addresses collected at the baseline visit to the web -
based s urvey vendor via secure portal . MGH  staff will review the consent  (either in person or via 
telephone)  and answer any questions. MGH  staff will confirm the email address with the 
participant during the initial screening process.  
Participants  (patients and MGH staff)  will also be informed of their rights as a participant, 
including that they may refuse to take part or withdraw at any time without penalty or giving up 
any benefits to which they are otherwise entitled.  The participants also will be informed th at, 
should they choose not to participate in all or any part of the study, their current or future 
treatment at the site will not be affected.  
This study involves participant -completed measures for information purposes only; the study does 
not involve the use of an investigational drug or device.  There are no known risks or benefits to 
participants.  During or following the research study, patients may become more aware of how 
they feel about their condition â€”and how their condition may affect certain aspects  of their life.  
Patients will be encouraged to talk with their asthma provider about their questions or concerns.  
The elements of federal regulations pertaining to consent procedures, disclosure of potential risks 
and benefits, and patient confidentiality will be strictly observed.  
6.2.2 Confidentiality of Study/Patient Data  
All data collected will be strictly confidential, in accordance with local, state, and federal law.  
Personnel from the following organizations  may examine the research study records: Evidera,  AZ, 
and regulatory agencies (such as the FDA and the IRB).  Only MGH  staff involved in participant 
recruitment, clinical data extraction, and questionnaire administration will know the identities of 
the patients.  Staff will be instructed to maintain comple te confidentiality of all collected data.  
Participant data files collected by [CONTACT_825467] a 
locked file cabinet separate from their identifying information and  will be destroyed per Evideraâ€™s 
SOPs after a period of seven years.  The summary report generated from the completed 
questionnaires w ill not contain any participant -identifying information.  Medical data collected 
will not be associated with personal health identification data.  All study data will be de -identified.  
Evidera retains records for a minimum of two years on site, and an additi onal five years off site.  
Upon enrollment, participants will be assigned unique identification numbers.  These unique 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144622] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 32 
 identifiers will be used to track the participants throughout the study.  Only the unique participant 
identification numbers and participant  initials will be entered into the database and recorded on 
the participant questionnaires â€”not participant names.  
This interventional study will be performed in accordance with ethical principles that are 
consistent with the Declaration of Helsinki, Intern ational Council for Harmonization  (ICH), Good 
Clinical Practice (GCP), and the applicable legislation on Interventional Studies.  
The investigators will perform the clinical pi[INVESTIGATOR_825437], and in 
accordance with currently acceptable techniques and know -how.  
The final clinical pi[INVESTIGATOR_182239], including the final version of the Patient and MGH 
Informed Consent Form, must be app roved or given a favorable opi[INVESTIGATOR_825435]/IRB/Independent Ethics Committee (IEC).  
The Ethics Committee/IRB/IEC must also approve any protocol amendment and all advertising 
used to recruit subjects for the study, according to loc al regulations.  
6.3 Collection  and Report ing of Adverse Events/Adverse Drug Reactions  
6.3.[ADDRESS_1144623] adverse events during  the 
study  since enrollment in the study is based on disease diagnosis and does not require the 
administration of an AZ drug. However, if an investigator (or patient) would  like to report an AE 
that is not required to be collected, this can be reported as a spontaneous report according to local 
regulations.  The open -ended question in the feedback section of the App will be monitored for AE 
reporting by [CONTACT_825468] . 
6.3.2 Reporting of Adverse Events  
It is not necessary to report potential AEs based on answers to the ACTTM. 
The rationale is , the signs and symptoms collected by [CONTACT_825469]. It is not feasible to evaluate associat ions between a specific drug and events 
reported by [CONTACT_825470].  According to the literature, more than 50% of asthma 
patients who are under med ication will have such signs and symptoms.   
Patients will be informed that their healthcare providers (including MGH  staff and their clinician) 
will not be reviewing their responses to the study questionnaires in real time. They will be 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144624] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 33 
 instructed to repor t any health concerns or issues that they may experience directly to their 
healthcare providers.  
6.3.3 Aggregate Safety Review from PRO Instruments  
An aggregate data report (in the form of a summary) of the PROsâ€™ scores from patients on AZ 
product(s) will be provided to the Global Safety Physician (GSP) and Safety Surveillance and 
Management Team (SSaMT) Lead for their review at the end of the study, so that the data can be 
considered in the context of the overall benefit: risk assessment of the product(s).  
  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144625] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 34 
 7. REFERENCES  
1. Moore WC, Bleecker ER, Curran -Everett D, et al. Characterization of the severe 
asthma phenotype by [CONTACT_572], Lung, and Blood Institute's Severe Asthma 
Research Program. J Allergy Clin Immunol. 2007;119(2):[ADDRESS_1144626]. Asthma 
Research and Practice. 2017;3(1):1.  
3. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a 
survey for assessing asthma control. J Allergy Clin  Immunol. 2004;113(1):59 -65. 
4. Bangor A, Kortum PT, Miller JT. An Empi[INVESTIGATOR_825438]. International Journal of Human â€“Computer Interaction. 2008;24(6):574 -594. 
5. Marshall GN HR. The Patient Satisfaction Questionnaire Short -Form (PSQ -18). In. 
Santa Monica, CA: Rand Corp.; 1994.  
  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144627] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144628], please confirm the following from the patientâ€™s chart:  
The patient has a clinical diagnosis of asthma  Confirmed ï‚£ 
The patient is at least 18 years of age  
(Recruitment quota: approximately  33 young adult patients 
(18â€“35 years of age ) Confirmed ï‚£ 
Recruitment Quota only:  
New patients to the practice (less than 3 -month history) and 
with uncontrolled asthma  Confirmed ï‚£ 
Recruitment Quota only:  
At least one exacerbation per year   Confirmed ï‚£ 
 
Introductory Script for Clinical Pi[INVESTIGATOR_825439] [patient name], my name [CONTACT_832] [interviewer name] and I am working with MGH and 
[COMPANY_008] on a research study to evaluate a new smart phone app called AMAZEâ„¢ to monitor 
asthma symptoms and to provide resources that may be helpful for asthma patients like you. I will 
provide  some basic information about this study and ask you some questions to find out if you 
might qualify for the study. This conversation will take about 20 minutes, is this a good time to 
talk? _____Yes  _______ No  
If no, thank you for your time today!  
If yes, thank you for your interest.  
We are participating in a research study with Evidera and [COMPANY_008], a health outcomes 
research organization and Pharmaceutical company, to evaluate a new patient App that will help 
you monitor your asthma daily and provi de resources that may be helpful for asthma patients like 
you. The goal of this study is to see if the patient App helps improve your care. Information from 
your medical records, such as your age, medications, existing medical conditions, will be 
collected  for this study.  
You will be asked to use the App over the next six months by [CONTACT_825471]. A brief sociodemographic form 
will be sent via email for your completion, as we ll as periodic surveys to gain additional  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144629] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 36 
 information about your experiences using the App. If you agree to participate, you will be emailed 
a link to download the App with a unique ID. You will be compensated $10 for each visit 
completed and paid at basel ine, months 1, 3 and 6 for a potential total of $40.  
As a part of this study, some participants will be randomly selected to complete a series of 
telephone interviews (around 1, 3, and 6 months after enrolling in the study) or just one interview 
(around 2,  4, or 5 months after enrolling in the study) to be conducted by [CONTACT_825472] . 
If selected for the interviews, the interview will be audio recorded  and transcribed by a third -party 
vendor (TransPerfect),  and should last approximately 30 to 45 min utes.  
Subjects will get $10 for each visit completed and $[ADDRESS_1144630] may receive for completion of visits is $40. Subjects will be randomized into one of three 
groups. Participants will only complete one of these group s: 
4. Longitudinal (three total) interviews and receive up to $265  
5. Cross -sectional (one -time) interviews and receive up to $115  
6. Not randomized to be interviewed and receive up to $[ADDRESS_1144631] benefits f or you; however, 
information from this study may help health care providers improve the way they ask patients 
questions about their asthma.  
The risks of the study are expected to be minimal. There is the risk that allowing us to record your 
name [CONTACT_825478] a possible loss of 
confidentiality. We will take reasonable steps to protect the confidentiality of your information.  
Taking part in this study is voluntary. You may choose not to take part in this study, o r if you 
decide to take part, you can change your mind later and withdraw from the study. Your decision 
will not change any present or future relationships with MGH or its affiliates.  
Are you interested in participating this study? _____Yes  _______ No  
If no, thank you for your time today!  
If yes, thank you for your interest.  
Before moving forward, would you be willing to answer some questions to find out if you might 
qualify for the study? I will record your answers in writing, but only collect detailed  contact 
[CONTACT_825473]. May I begin? _____Yes  _______ No  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144632] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144633] a smartphone with internet access? _____Yes  _______ No  
 
If yes, what type of smartphone and operating system do you have?  
_____iPhone (OS an d Type)  _______ Android (OS) _____Other  
 
If the participant does not have an iPhone 8 or newer with an Operating System of 13 or newer or 
an Android with an Operating System of 8.0 or newer, the participant is not eligible to participate 
and thank them f or their time!  
 
 
As a part of the study  you will be sent an emailed link with your unique ID to log -in to the 
application as well as instructions for how to download the app.  
 
 
I need to collect some information from you to share with Evidera in order to make your profile 
for the reloadable gi ft card, ClinCard, and share your email address for sending you the study 
consent form and for future survey completion.  
 
 
Do you grant permission for the study team to send you the full study consent form via email for 
you to review and sign? _____Yes  _______ No  
 
 
Do you grant permission for the study team to leave a brief voice mail message if you are not 
available when the study team schedules calls? _____Yes  _______ No  
  
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
&RQWDFW,QIRUPDWLRQ$0$=(70$SS

'HDU5HVHDUFK3DUWLFLSDQW7KDQN\RXIRUWDNLQJSDUWRIWKH$0$=(ÂŒ$ VWKPD5HVHDUFK6WXG\D W0DVVDFKXVHWWV*HQHUDO
+RVSLWDO0*+$VSDUWRIWKHVWXG\SURFHGXUHSOHDVH FRPSOHWHWKHIRUPEHORZ WRFRQILUP\RXUFRQWDFW
LQIRUPDWLRQ7KLVZLOOEHXVHGWRV HWXS\RXUSURILOHIRUSD\PH QW

,I\RXKDYHD Q\TXHVWLRQVSOHDVHFRQWDFWWKH6WXG\7HDPDW  
7KDQN\RX 

)LUVW1DPH3OHDVHHQWHU\RXU)LUVW1DPHLQIXOOGRQRWXVHDQ 
LQLWLDOBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB/DVW1DPH3OHDVHHQWHU\RXU /DVW1DPHLQIXOOGRQRWXVHDQ
LQLWLDOBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB

'DWHRIELUWKBBBBBBBBBBBBBBB

6WUHHWRU32$GGUHVVBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB&LW\BBBBBBBBBBBBBBBBBBBBBB 6WDWHBBBBBBBBBB =LSFRGHBBBBBBBBB BBB
3KRQH1XPEHU+RPHBBBBBBBBBBBB:RUN &HOOBBBBBBBBBBBB
(PDLOBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
'R\RXJUDQWSHUPLVVLRQIRUWKHVWXG\W HDPWROHDYHDEULHIYRL FHPDLOPHVVDJHLI\RXDUHQRW
DYDLODEOHZKHQWKHVWXG\WHDPVFKHGXOHVFDOOV"
Â…<HV
Â…1R
3UHIHUUHGORFDWLRQWRFDOO
Â…+RPH
Â…:RUN
Â…&HOO

%HVWWLPHWRFDOO0RQGD\)ULGD\DPSP CCI
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144634] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144635]:   
AMAZETM Health Management MGH  Asthma Mobile App Study â€“ Electronic Consent Form  
 
Body of Consent E -mail:  
Dear [Participant]:  
Thank you for your interest in our research study about a newly developed mobile app for asthma 
patients.   
 
Prior to participating in  the study, you will need to provide consent electronically.  When 
instructed  to do so by [CONTACT_825474], please go to the following URL:  <insert consent URL>  
  
 
Thank you,  
 
<insert MGH contact [CONTACT_825475]>  
 
  
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
$33(1',;&5(&58,70(17(0$,/$1')/<(5
5HFUXLWPHQWHPDLOWREHVHQWWRWKHSDWLHQWSDUWLFLSDQWV
6XEMHFW0*+$0$=($VWKPD6WXG\3DUWLFLSDWLRQ
$WWDFK0*+)O\HU3') FKHFNODWHVWYHUVLRQRIWKLV 

'HDU6DOXWDWLRQ/DVW1DPH

:HLQYLWH\RXWRSDUWLFLSDWHL QDUHVHDUFKVWXG\DORQJVLGH$VWU D=HQHFD DSKDUPDFHXWLFDOFRPSDQ\ DQG
(YLGHUDDKHDOWKRXWFRPHVUHVHDUFKRUJDQL]DWLRQ WRHYDOXDWHDVPDUWSKRQHDSSOLFDWLRQ DSSFDOOHG
$0$=(70WKDWPD\DVVLVW\RXLQPRQLWRUL QJ\RXUDVWKPDRQDGDLO\EDVLV 7KHRYHUDOOJRDORIWKLVVWXG\
LVWRHYDOXDWHLIWKHSDWLHQW$SSKHOSVLPSURYHV\RXUFDUH

,ILQWHUHVWHGDQG\RXGHFLGHWRS DUWLFLSDWHLQWKLVYROXQWDU\ VWXG\\RXZLOOEHDVNHGWRXVHWKH$SSIRUVL[
PRQWKVE\FRPSOHWLQJDGDLO\DVVHVVPHQWORJV aPLQXWHSHUGD\ <RXZLOODOVREHDVNHGWRFRPSOHWH
SHULRGLFXVHUIHHGEDFNVXUYH\V WRJDLQLQVLJKWDERXW\RXUH[SHU LHQFHVXVLQJWKH$SS7KHUHZLOOEHWRWDORI
DSSUR[LPDWHO\VXUYH\VWKURXJKRX WWKHVWXG\DQGZRXOGWDNHQR PRUHWKDQDIHZPLQXWHVWRFRPSOHWH
HDFKDQG\RXZRXOGUHFHLYHWRWDOI RUFRPSOHWLRQRIDOOVXU YH\V)RUWKLVVWXG\LI\RXFKRRVHWR
SDUWLFLSDWHVRPHSDUWLFLSDQW VZLOODOVREHDVNHGWREHUDQGRPO \VHOHFWHGWRFRPSOHWHDVHWRIWKUHH
WHOHSKRQHLQWHUYLHZV RUDRQHWLPHLQWHUYLHZ ZKLFKZLOOEHFRQGXFWHGE\(YLGHUDRXUKHDOWKRXWFRPHV
FROODERUDWRU)RUWKHVHDGGLWLRQDOLQWHUYLHZV\RXZLOOEHSDLG IRUHDFKFRPSOHWHGLQWHUYLHZ LI
UDQGRPO\VHOHFWHG 

7KHULVNVRIWKHVWXG\DUHH[SHFW HGWREHPLQLPDO7KHUHLVWKH ULVNWKDWDOORZLQJXVWRUHFRUG\RXUQDPH
ZLWK\RXUDQVZHUVDQGDFFHVVLQJ\RXUKHDOWKLQIRUPDWLRQLVDSR VVLEOHORVVRIFRQILGHQWLDOLW\:HZLOOWDNH
UHDVRQDEOHVWHSVWRSURWHFWWKHFRQILGHQWLDOLW\RIDOO\RXULQI RUPDWLRQ
,I\RXDUHLQWHUHVWHGSOHDVHUHVSRQGWRWKLVHPDLODQGZHFDQ VHWXSDEULHIGLVFXVVLRQWRDGGUHVVSURMHFW
GHWDLOVDQGWKHLQIRUPHGFRQVH QWGRFXPHQWDWLRQ)ROORZLQJWKHL QIRUPHGFRQVHQWSURFHVVZHFDQWKHQ
GRZQORDGWKHDSSDQGVHWXS\RXUDFFRXQW

$WWDFKHGLVWKHVWXG\IO\H USURYLGLQJDEULHILQWURGXFWLRQWRW KHDSS

:HORRNIRUZDUGWR\RXUUHVSRQVHHLWKHUZD\

7KDQNVLQDGYDQFH


6LJQDWXUHEORFNRISURYLGHUDQGHLWKHU RU 

0*+$0$=(70$VWKPD6WXG\7HDP
0DVVDFKXVHWWV*HQHUDO+RVSLWDO)UXLW6W%RVWRQ0$

[COMPANY_003] [COMPANY_003]
CCI
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
5HFUXLWPHQWHPDLOWREHVHQWW RWKHFOLQLFDOVWDIIUHVHDUFKSDU WLFLSDQW
'HDUBBBBBBBBBBBBBBB
7KDQN\RXIRU\RXULQWHUHVWLQRXUUHVHDUFKVWXG\DERXWDQHZO\ GHYHORSHGPRELOHDSSIRUDVWKPDSDWLHQWV
,QWKLVUHVHDUFKVWXG\ZHZDQW WRHYDOXDWHWKH$0$=(ÂŒ$SSWRKH OSPRQLWRU0*+DVWKPDSDWLHQWV7KH
JRDORIWKLVVWXG\LVWROHDUQDERXW WKHLPSDFWRIWKLVGLJLWDO GLVHDVHPDQDJHPHQWSODWIRUPRQWKHTXDOLW\RI
OLIHRXWFRPHVDQGWUHDWPHQWRIDVWKPDSDWLHQWV
,I\RXGHFLGHWRMRLQWKLVUHVHDUFKVWXG\LWZLOOWDNH\RXDER XWPRQWKVWRFRPSOHWHWKHVWXG\<RXZLOOEH
DVNHGWRSURYLGH\RXUSHUVRQDORSLQLRQE\FRPSOHWLQJWKHSRVW VWXG\VXUYH\DQGV\VWHPXVDELOLW\VFDOH
VXUYH\VDVD0*+FOLQLFDOVW DIILQYROYHGLQWKHVWXG\WRJDL QDGHHSHUXQGHUVWDQGLQJRIWKHIHDVLELOLW\RI
LPSOHPHQWLQJWKHDVWKPD$0$=(70SODWIRUP7KHUHZLOOEHDWRWDORIVXUYH\VWKURXJKRXWWKHUHV HDUFK
VWXG\DQGZRXOGWDNHQRPRUHWKDQDIHZPLQXWHVWRFRPSOHWHHDF KVXUYH\DQG\RXZLOOQRWEHSDLGIRU
FRPSOHWLQJWKHVHVXUYH\V 

3ULRUWRSDUWLFLSDWLQJLQWKH VWXG\\RXZLOOQHHGWRSURYLGHF RQVHQWHOHFWURQLFDOO\ :KHQLQYLWHGWRGRVR
E\WKHVWXG\VWDIISOHDVHJRWRWKHIROORZLQJ85/ LQVHUWFRQVHQW85/! 

)RUTXHVWLRQVSOHDVHVHQGDQHPDLOWRWKHVWXG\WHDP 

7KDQNV

0*+$0$=(70$VWKPD6WXG\7HDPCCI
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB

CCI
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144636] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 43 
 11. APPENDIX D. INTRODUCTORY EMAIL  
The code and invitation code expi[INVESTIGATOR_825440].  
   

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144637] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 44 
 12. APPENDIX E. AMAZETM PATIENT MOBILE APPLICATIO N 
SCREENSHOTS  
12.1 Flyer for App  
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144638] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 45 
 12.2 Account Creation and Login  
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144639] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 46 
       

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144640] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 47 
  

6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
 
[COMPANY_003]
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144641] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 49 
          
12.3 Terms of Use  
AZ - MGH - AMAZE 
DMP - Clinician Portal Terms of Use (12.1.20).docx
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144642] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 50 
 
AZ - MGH - AMAZE 
DMP - Privacy Policy (12.1.20).docx 
AZ - MGH - AMAZE 
DMP - Patient Terms of Use (12.1.20).docx
 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144643] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 51 
 12.4 Air Quality  
            

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144644] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 52 
        

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144645] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 53 
          
12.5 Appointments  
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144646] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144647]  
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144648] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 55 
  

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144649] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 56 
  

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144650] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 57 
          

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144651] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 58 
          

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144652] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 59 
 12.7 Daily Asthma Log  
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144653] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 60 
           

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144654] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 61 
        

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144655] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 62 
        

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144656] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 63 
          

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144657] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 64 
        

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144658] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 65 
  

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144659] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 66 
 12.8 Education  
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144660] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144661] Reset  
 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144662] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 68 
 12.10  Home  
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144663] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 69 
 12.11  Messages  
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144664] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 70 
        

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144665] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 71 
  

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144666] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 72 
 12.12  Feedback  
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144667] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 73 
 12.13  My Plan  
     

6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
  
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB


[COMPANY_003]
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144668] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 76 
 12.14  Notifications  
          

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144669] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 77 
 12.15  Settings  
 

6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB

CCI
CCICCI
[COMPANY_003]
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144670] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 79 
       

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144671] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 80 
  

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144672] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 81 
 12.16  Trends  
 

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144673] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 82 
      

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144674] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 83 
        

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144675] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 84 
  

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144676] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 85 
 12.17  Study Ending  
 

6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
 

[COMPANY_003]
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003][COMPANY_003]
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144677] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 87 
 13. APPENDIX F. CLINICAL CASE REPORT FORM  
Clinical Case Report Form  
 
Screening ID  
__________________________________  
Participant ID  
__________________________________  
BI linked ID  
__________________________________  
Date of Enrollment  
__________________________________  
 
Confirmation of Eligibility Into the Study  
Patient is â‰¥ 18 years of age at the time of enrollment?  
Yes 
No 
 
Patient diagnosed with asthma?  
Yes 
No 
 
Patient has access to smartphone with internet access with the following requirements: iOS 
(Operating System iOS 13 or newer and Devices iPhone 8 or newer) or Android (Operating 
System 8.0 or newer)?  
Yes 
No 
 
Patient is able to understand and speak English sufficiently to be able to use the AMAZEâ„¢ 
patient app?  
Yes 
No 
 
Patient provided consent to participate?  
Yes 
No 
 
Does the patient have a cognitive impairment, hearing difficulty, visual impairment, acute 
psychopathol ogy, medical condition, or insufficient knowledge of the English language that, in 
the opi[INVESTIGATOR_825441], would interfere with his or her ability to provide 
electronic consent and/or participate/complete the questionnaire?  
Yes 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144678] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 88 
 No  
(If yes - patient CANNOT be enrolled into the study)  
 
Investigator/Coordinator Full Name  
[CONTACT_825479]/Coordinator Signature: _____________________________________    
Date:  _____________________  
 
Did the patient download the AMAZE DMP App? _____ yes, _____ no  
IF YES, please record the BrightInsight ID Number: _________________ (Add a comment if BI 
ID has not been provided yet.)  
 
Patient Characteristics    
  Sex:  ï‚£ Male   ï‚£ Female  Age (years): ___  Height:  _____ ft ___ in; Weight: ____ lb  
ASTHMA DIAGNOSIS  
Age when first diagnosed with asthma: _____(Years (if unknown, please mark the box below))   
ï‚£ Unknown  
Duration patient seen by a health care provider for asthma: __ years __months  
Duration patient seen by a healthcare provider at MGH for asthma: __years __months  
Smoking status (tobacco products, electronic cigarettes, vapi[INVESTIGATOR_007], marijuana)  
Smoking Status ï‚£ Never smoked ï‚£ Previously Smoker ï‚£ Current Smoker  
Previously smoked ï‚£ Cigarettes  ï‚£ Vapi[INVESTIGATOR_007]  ï‚£ Marijuana  
Number of years smoked __________________  
Average cigarette packs/vapi[INVESTIGATOR_825442]: __________________  
Choose an option to Record â€œTime Since Last Smokeâ€ ï‚£ Weeks ï‚£ Months ï‚£ Years  
Time since last smoked:  
Weeks _________________ (Weeks)  
Months ________________ (Months)  
Years __________________ (Years)  
 
Currently smoking ï‚£ Cigarettes  ï‚£ Vapi[INVESTIGATOR_007]  ï‚£ Marijuana  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144679] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 89 
 Number of years smoked __________________ (Years)  
Average cigarette packs/vapi[INVESTIGATOR_825442]: __________________  
Date last smoked: _____________ (Date)  
Time last smoked: _____________ (Time)  
Was spi[INVESTIGATOR_825443] n testing performed on this patient in the last 12 months?  
ï‚£ Yes  ï‚£ No 
Date of the most recent Spi[INVESTIGATOR_328693] __________________  
 
FEV1: Liters __________________ (Liters)  
FEV1: % Predicted __________________ (% Predicted)  
FVC: Liters __________________ (Liters)  
FVC: % Predicted __________________ (% Predicted)  
FEV1:FVC: __________________  
FEV1/FVC: % Predicted __________________ (% Predicted)  
 
Was a test for eosinophil blood count performed on this patient in the last 12 months?   
      ï‚£  Yes   ï‚£  No 
Date of highest Absolute Eosinophil Count Test __________________  
Absolute Eosinophil Count (Highest) __________________ (Absolute Eosinophil Count)  
How would you rate this patientâ€™s asthma severity?  
ï‚£ Intermittent  
ï‚£ Mild persistent  
ï‚£ Moderate persistent  
ï‚£ Severe persistent  
At the last visit, do you think patient was:  
ï‚£ Well controlled (NO hospi[INVESTIGATOR_825444] 12 months)  
ï‚£ Not well controlled (NO hospi[INVESTIGATOR_602], and [ADDRESS_1144680] 
12 months)  
ï‚£ Very poorly controlled (1+ hospi[INVESTIGATOR_059], and/or 2+ ER visits, and/or 2+ steroid 
prescriptions in the past 12 months)  
MAINTENANCE PHARMACOLOGIC THERAPY  
Please only include current medication the patient is currently prescribed and taking . Please check  all that apply.  
ICS 
ï‚£ QVAR HFA/Redihaler (beclomethasone 
dipropi[INVESTIGATOR_16847])  
ï‚£ Beclovent  HFA (beclomethasone 
dipropi[INVESTIGATOR_16847])  
ï‚£ Vanceril HFA) (beclomethasone dipropi[INVESTIGATOR_16847])  
ï‚£ Pulmicort Flexhaler/Respules (budesonide)  
ï‚£ Aerospan (flunisolide)  
ï‚£ Flunisolide  
ï‚£ Flovent HFA/Disc (fluticasone propi[INVESTIGATOR_16847])  LAMA  
ï‚£ Incruse Ellipta (Umeclidinium)  
ï‚£ Spi[INVESTIGATOR_342403]/Handihaler (tiotropi[INVESTIGATOR_1893])  
ï‚£ Tudorza/Aclidinium (aclidinium bromide)  
Triple Therapy (fixed dose combination)  
ï‚£ Trelegy Ellipta (fluticasone/umeclidinium/vilanterol)  
LTRA  
ï‚£ Singulair (Montelukast)  
ï‚£ Accolate (Zafirlukast)  
ï‚£ Zyflo (Zileuton)  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144681] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 90 
 MAINTENANCE PHARMACOLOGIC THERAPY  
Please only include current medication the patient is currently prescribed and taking . Please check  all that apply.  
ï‚£ Azmanex Twisthaler/HFA (mometasone 
furoate)  
ï‚£ Arnuity Ellipta (fluticasone furoate inhalation  
powder))  
ï‚£ Triamcinolbone Acetonide  
ï‚£ Alvesco  
ICS/LABA  
ï‚£ Advair Diskus/HFA (fluticasone propi[INVESTIGATOR_825445])  
ï‚£ Wixela Inhub  (fluticasone propi[INVESTIGATOR_177531])  
ï‚£ Airduo Respi[INVESTIGATOR_342407] (fluticasone propi[INVESTIGATOR_825445])  
ï‚£ Breo Ellipta (fluticasone furoate and vilanterol)  
ï‚£ Dulera HFA (mometasone furoate and 
formoterol fumarate dihydrate)  
ï‚£ Symbicort (budesonide/formoterol fumarate  
dihydrate)  
ï‚£ Budesonide/formoterol  
LABA (Single inhaled medicine, not in a fixed 
dose combination with an ICS or ICS/LAMA)  
 
ï‚£ Serevent  (Salmeterol xinafoate)  
ï‚£ Foradil (formoterol fumarate)  
ï‚£ Arcapta (Indacaterol)  
ï‚£ Brovana ( arformoterol tartrate)  
ï‚£ Indacaterol  
ï‚£ Arformoterol  
ï‚£ Striverdi  (Oldaterol)  Theophylline Preparations  
ï‚£ Theo -24 (Theophylline)  
ï‚£ Elixophylline (Theophylline)  
ï‚£ Theochron (Theophylline)  
Chronic Add -on Therapy (Macrolides)  
ï‚£ Zithromax (Azithromycin                 )  
ï‚£ Biaxin (Clarithromycin)  
ï‚£ Erythromycin (Erythrocin)  
Biologics  
ï‚£ Cinqair (reslizumab)  
ï‚£ Dupi[INVESTIGATOR_12460] (dupi[INVESTIGATOR_12458])  
ï‚£ Fasenra (benralizumab)  
ï‚£ Nucala (mepolizumab)  
ï‚£ Xolair (omalizumab)  
 
SABA/Rescue Inhaler Use  
ï‚£ Daily Use (SABA)  
ï‚£ SABA alone  
ï‚£ SABA+ICS  
ï‚£ LABA+ICS  
ï‚£ Nebulizer  
ï‚£ SAMA  
Nebulizer â€“ Please Specify 
______________________  
ï‚£ Other  â€“ Please Specify 
______________________   
Which of the following did you do to the patientâ€™s medication after their LAST visit? (Check all that apply)  
ï‚£ Step-down of controller medicines  
ï‚£ No change of controller medicines  
ï‚£ Step-up of controller medicines  
ï‚£ Prescribe a course of systemic corticosteroids  
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
0$,17(1$1&(3+$50$&2/2*,&7+(5$3<
3OHDVHRQO\LQFOXGHFXUUHQWPHGLFDWLRQWKHSDWLHQWLV FXUUHQWO\SUHVFULEHGDQGWDNLQJ 3OHDVHFKHFN DOOWKDWDSSO\ 
Â…2WKHUBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
 
,QYHVWLJDWRU)LQDO&RQILUPDWLRQ
,QYHVWLJDWRU&RRUGLQDWRU6LJQDWXUHBBBBBBBBBBBBBBBBBBBBBBBBBBB BBBBBBBBBB
'DWHBBBBBBBBBBBBBBBBBBBB


$33(1',;*3$7,(17'(02*5$3+,&48(67,211$,5(
'HPRJUDSKLF4XHVWLRQQDLUH$0$=(ÂŒ$SS
'HDU5HVHDUFK3DUWLFLSDQW
7KDQN\RXIRUWDNLQJSDUWRIWKH$0$=(ÂŒ$ VWKPD5HVHDUFK6WXG\D W0DVVDFKXVHWWV*HQHUDO
+RVSLWDO0*+
$VSDUWRIWKHVWXG\SURFHGXUHSOHDVHFRPSOHWHWKHVXUYH\EHOR Z

,I\RXKDYHDQ\TXHVWLRQVSOHDVH FRQWDFWWKH6WXG\7HDPDW 
7KDQN\RX

:KDWLV\RXUDJH"BBBBB\HDUV

:KDWLV\RXUELRORJLFDOVH["
Â…0DOH    
Â…)HPDOH
:KDWLV\RXUHWKQLFEDFNJURXQG"
Â…+LVSDQLFRU/DWLQR
Â…1RW+LVSDQLFRU/DWLQR
Â…3UHIHUQRWWRVD\
:KDWLV\RXUUDFLDOEDFNJURXQG"CCI
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144682] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 92 
 ï‚£ White  
ï‚£ Black or African American  
ï‚£ Asian  
ï‚£ Native Hawaiian or other Pacific Islander  
ï‚£ American Indian or Alaska Native  
ï‚£ Other (specify): ____________________________________  
ï‚£ Prefer not to say  
 
 
What is your current living/domestic situation?  
ï‚£ Living alone  
ï‚£ Living with a spouse, partner, family, or friends  
ï‚£ Other (specify): _______ ______________________  
 
How would you describe your employment status?  
ï‚£ Employed, full -time 
ï‚£ Employed, part -time 
ï‚£ Homemaker  
ï‚£ Student  
ï‚£ Unemployed  
ï‚£ Retired  
ï‚£ Disabled  
ï‚£ Other (specify): _________________________________________________  
 
  What is the highest level of education you have completed?  
ï‚£ Less than high school  
ï‚£ Secondary/high school  
ï‚£ Associate degree, technical or trade school  
ï‚£ College/university degree  
ï‚£ Postgraduate school  
ï‚£ Other (specify): _________________________________________________  
 
  What is your householdâ€™s total income from all sources over the past 12 months?  
ï‚£ Less than $15,000  
ï‚£ $15,000 to $29,999  
ï‚£ $30,000 to $44,999  
ï‚£ $45,000 to $59,999  
ï‚£ $60,000 to $74,999  
ï‚£ $75,000 to $99,999  
ï‚£ $100,000 or more  
ï‚£ Prefer not to answer  
 
 Age when you were first diagnosed with asthma? _____ (year -old) 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144683] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 93 
  
 How many years (and months) seen by a health care provider for asthma with asthma  
 _____ (years (and months))  
 
   How many years (and months) seen by a MGH provider for asthma with asthma  
   _____ (years (and months))  
 
  Do you currently smoke?  
ï‚£ Yes, smoker  
ï‚£ Not currently, but previous smoker  
ï‚£ No, never smoked  
 
 
  Do you currently vape?  
  ï‚£ Yes, vaper  
  ï‚£ Not currently, but previous vaper  
  ï‚£ No, never vaped  
 
  Do you have any of the following health conditions? (Check all that apply)  
ï‚£ No other health conditions  
ï‚£ Allergy diagnosed by [CONTACT_825476]  
ï‚£ Allergic rhinitis (nasal allergies, â€œhay feverâ€)  
ï‚£ Heart disease (history of heart attack, heart failure or heart valve problems)  
ï‚£ Anxiety  
ï‚£ Anaphylaxis (severe allergic reaction to a food, bee sting, allergy shot, medication or other)  
ï‚£ Arthritis  
ï‚£ Aspi[INVESTIGATOR_79948] (aspi[INVESTIGATOR_825446], swelling or breathing problems)  
ï‚£ Atopic dermatitis/Eczema  
ï‚£ Chronic bronchitis  
ï‚£ Chronic Obstructive Pulmonary Disease (COPD)  
ï‚£ Chronic sinusitis  
ï‚£ Depression  
ï‚£ Diabetes  
ï‚£ Emphysema  
ï‚£ GERD (heartburn/reflux)  
ï‚£ Hypertension (high blood pressure)  
ï‚£ Nasal Polyps  
ï‚£ Sleep Apnea  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144684] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 94 
 ï‚£ Stroke  
ï‚£ Other (specify): ________________________________________________________  
ï‚£ Donâ€™t know  
 
Do you currently have health insurance?  
ï‚£ Yes  
ï‚£ No  
ï‚£ Prefer not to answer  
 
[Programmer note: If answered â€œyesâ€] What type of health insurance coverage do you have? 
(Check all that apply)  
ï‚£ Third -party payer (for example, United Healthcare, Blue Cross/Blue Shield, Aetna. )  
ï‚£ Managed care organization  
ï‚£ Tricare (military health insurance)  
ï‚£ Medicare  
ï‚£ Medicaid (MassHealth)  
ï‚£ Self-pay 
ï‚£ Unsure  
ï‚£ Other (please specify): ___________________________  
 
  
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
$33(1',;+3$7,(179, 6,7(;3(5,(1&(6859(<
9LVLW([SHULHQFH6XUYH\$0$=(ÂŒ$SS

'HDU5HVHDUFK3DUWLFLSDQW
7KDQN\RXIRUWDNLQJSDUWRIWKH$0$=(ÂŒ$ VWKPD5HVHDUFK6WXG\D W0DVVDFKXVHWWV*HQHUDO
+RVSLWDO0*+$VSDUWRIWKHVWXG\SURFHGXUHSOHDVH FRPSOHWHWKHVXUYH\EHOR Z

,I\RXKDYHDQ\TXHVWLRQVSOHDVH FRQWDFWWKH6WXG\7HDPDW 

7KDQN\RX
<RXÂ¶YHEHHQXVLQJWKH $0$=(ÂŒ $SSWRWUDFN\RXUDVWKPDV\PSWRPVDQGILQGPRUHLQIRUPDWLRQ
RQDVWKPD3OHDVHDQVZHUWKHIROORZLQJTXHVWLRQVNHHSLQJLQPL QGKRZWKHXVHRIWKH $0$=(ÂŒ 
$SSPD\KDYHDIIHFWHG\RXUFOLQLFH[S HULHQFH\RXKDGUHFHQWO\
<RXUUHVSRQVHVDUHVWULFWO\FRQILGH QWLDODQGZLOOQRWDIIHFW\R XUFOLQLFDOFDUHLQDQ\ZD\
:DVWKHYLVLWLQLWLDWHGE\FKHFNRQH
Â…3DWLHQW
Â…+HDOWKFDUH3URYLGHU
 6WURQJO\
$JUHH$JUHH 1HXWUDO 'LVDJUHH 6WURQJO\
'LVDJUHH
7KH$0$=(ÂŒ $SS
KHOSHGPH GLVFXVVP\DVWKPD
ZLWKP\KHDOWKFDUH
SURYLGHUVGXULQJP\PRVW
UHFHQWYLVLWÆ‘1RW
DSSOLFDEOH
Â…Â…Â… Â… Â…
,UHFHLYHGLQIRUPDWLRQ
DERXWP\DVWKPDWKDWKHOSHG
PHEHWWHUXQGHUVWDQGP\
FRQGLWLRQGXULQJP\PRVW
UHFHQWYLVLWÆ‘1RW
DSSOLFDEOH
Â…Â…Â… Â… Â…
,UHFHLYHGLQIRUPDWLRQ
DERXWP\DVWKPDPHGLFDWLRQV
GXULQJP\PRVWUHFHQWYLVLWÆ‘1RW
DSSOLFDEOH Â…Â…Â… Â… Â…
,ZDVJLYHQLQIRUPDWLRQ
DERXWDGGLWLRQDOFDUHWKDW,Æ‘1RW
DSSOLFDEOHÂ…Â…Â… Â… Â…CCI
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144685] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144686] recent visit  
6) I was included in making 
decisions about my asthma 
treatment during my most 
recent visit  â–¡ Not 
applicable  ï‚£ ï‚£ ï‚£ ï‚£ ï‚£ 
7) The AMAZEâ„¢  App 
helped the appointment with 
my doctor go more smoothly.  â–¡ Not 
applicable  ï‚£ ï‚£ ï‚£ ï‚£ ï‚£ 
8) The time spent with my 
healthcare provider(s) 
discussing my asthma during 
my most recent visit was 
better compared to my last 
visit.  â–¡ Not 
applicable  
ï‚£ ï‚£ ï‚£ ï‚£ ï‚£ 
9) I found it was easier to 
schedule an appointment with 
my doctor using the 
AMAZEâ„¢  App â–¡ Not 
applicable  ï‚£ ï‚£ ï‚£ ï‚£ ï‚£ 
10) The visit helped avoid an 
ER or Urgent Care center 
visit or hospi[INVESTIGATOR_059]  â–¡ Not 
applicable  ï‚£ ï‚£ ï‚£ ï‚£ ï‚£ 
 
  
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
$33(1',;,3267678 '<6859(<)25+&36
3RVW6WXG\6XUYH\$0$ =(ÂŒ$SS&OLQLFDO6WDII5HVHDUFK3DUWLFL SDQW

'HDU&OLQLFDO6WDII5HVHDUFK3DUWLFLSDQW
7KDQN\RXIRUWDNLQJSDUWRIWKH$0$=(ÂŒ$ VWKPD5HVHDUFK6WXG\D W0DVVDFKXVHWWV*HQHUDO
+RVSLWDO0*+$VSDUWRIWKHVWXG\SURFHGXUHSOHDVH FRPSOHWHWKHVXUYH\EHOR Z

,I\RXKDYHDQ\TXHVWLRQVSOHDVH FRQWDFWWKH6WXG\7HDPDW  
7KDQN\RX
7KHSXUSRVHRIWKLVTXHVWLRQQDLUHLV WRREWDLQ\RXUIHHGEDFNRQ WKHLPSOHPHQWDWLRQRI$0$=(ÂŒ
7KLVTXHVWLRQQDLUHVKRXOGWDNHDSSUR[ LPDWHO\PLQXWHVWRFRPS OHWH$VDQHPSOR\HHRI0*+
\RXUSDUWLFLSDWLRQLVFRPSOHWHO\YRO XQWDU\DQGZLOOQRWLPSDFW \RXUMRELQDSRVLWLYHRUQHJDWLYH
PDQQHU$OOLQIRUPDWLRQFROOHFWHGIURP\RXZLOOEHNHSWZLWKRXW DQ\SHUVRQDOLQIRUPDWLRQ<RX
ZLOOEHLGHQWLILHGLQWKHUHVHDUF KUHFRUGVE\DFRGHQDPHRUQX PEHU%\FRPSOHWLQJWKLV
TXHVWLRQQDLUH\RXDUHDJUHH LQJWRSDUWLFLSDWHLQWKLVVWXG\
+RZZRXOG\RXUDWHWKHRYHUDOO HDVHRILPSOHPHQWLQJ$0$=(ÂŒRQDSODWIRUPLQWR\RXU
FOLQLFDOSUDFWLFH"
Â…9HU\HDV\
Â…6RPHZKDWHDV\
Â…1RWHDV\RUGLIILFXOW
Â…'LIILFXOW
Â…9HU\'LIILFXOW

'LGWKH$0$=(ÂŒKHOS\RXPDQDJH\RXUSDWLHQWV"
Â…1RWDWDOO
Â…6OLJKWO\
Â…6RPHZKDW
Â…0RGHUDWHO\
Â…9HU\ZHOO
5HJDUGOHVVRILQWHUPLWWHQWRUSH UVLVWHQWRQDYHUDJHZKDWSHUF HQWDJHRI\RXUDVWKPDSDWLHQWV
ZRXOG\RXFODVVLI\DV
BBB0LOGDVWKPD
BBB0RGHUDWHDVWKPD
BBB6HYHUHDVWKPD
 CCI
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144687] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 98 
  
On average, what percentage of your patients would you classify as:  
___ % Well -controlled  
___ % Not well -controlled  
___ % Very poorly controlled  
= 100%  
 
 
On average, what percentage of your asthma patients do you feel are at (1) low, (2) medium,  
and (3) high risk for adverse outcomes from th eir asthma? Please fill out below.  
 
___ % Low risk  
___ % Medium risk  
___ % High risk  
= 100%  
 
Did AMAZEâ„¢ help you identify patients who were at risk for adverse health outcome (e.g., 
hospi[INVESTIGATOR_165433], exacerbations, medication side effects) from their as thma that you would 
have otherwise missed?  
ï‚£ Yes 
ï‚£ No 
 
What did you find most useful about the AMAZEâ„¢ platform ? Check all that apply  
ï‚£ Ability to track symptoms  
ï‚£ Ability to asthma triggers  
ï‚£ Ability to track reliever medication use  
ï‚£ Ability track ER visits/ hospi[INVESTIGATOR_602]  
ï‚£ Ability to track air flow measurements  
ï‚£ Patient -HCP messaging feature   
ï‚£ Ability to assign another healthcare provider to a patient   
ï‚£ Integration of AMAZETM platform  with electronic health records  
ï‚£ Ability to track level of impairment through ACTâ„¢ scores  
ï‚£ Ability to receive alerts (flags) based on patient responses in the app  
ï‚£ Other: ____________________  
 
What did you find least useful or cumbersome about AMAZEâ„¢ plat form ? Check all that 
apply  
ï‚£ Ability to track symptoms  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144688] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 99 
 ï‚£ Ability to asthma triggers  
ï‚£ Ability to track reliever medication use  
ï‚£ Ability track ER visits/ hospi[INVESTIGATOR_602]  
ï‚£ Ability to track air flow measurements  
ï‚£ Patient -HCP messaging feature   
ï‚£ Ability to assign another healthcare provider to a patient  
ï‚£ Integration of AMAZETM platform with electronic health records  
ï‚£ Ability to track level of impairment through ACTâ„¢ scores  
ï‚£ Ability to receive alerts (flags) based on patient responses in the app  
ï‚£ Other   (Please Specify):  ____________________  
 
 
How frequently would you want to track the following for appropriate management of 
patients?  
Symptoms                          ï‚£ Daily ï‚£ Weekly ï‚£ Monthly ï‚£ Other__________  
Asthma triggers                  ï‚£ Daily ï‚£ Weekly ï‚£ Monthly ï‚£ Other__________  
Rescu e medication use       ï‚£ Daily ï‚£ Weekly ï‚£ Monthly ï‚£ Other__________  
Maintenance medication use     ï‚£ Daily ï‚£ Weekly ï‚£ Monthly ï‚£ Other__________  
Steroid medication use       ï‚£ Daily ï‚£ Weekly ï‚£ Monthly ï‚£ Other__________  
ER / Urgent Care visits        ï‚£ Daily  ï‚£ Weekly ï‚£ Monthly ï‚£ Other__________  
Peak flow / FEV1                   ï‚£ Daily ï‚£ Weekly ï‚£ Monthly ï‚£ Other__________  
 
Did AMAZEâ„¢ improve any of the following: Check all that apply  
ï‚£ Increased recognition of patients whose asthma placed their health at risk  
ï‚£ Increased recognition of conditions/risks, comorbidities driving poor asthma control  
ï‚£ Improved recognition of patient goals  
ï‚£ Improved patient engagement with their treatment, risk, or control  
ï‚£ Improved patient adherence with their treatment  
ï‚£ Improved efficiency of patient visit  
ï‚£ Increased educational efforts  
 
While using AMAZEâ„¢ disease management platform (DMP), how often did you change 
treatment?  
ï‚£ No different than before using the AMAZETM 
ï‚£ More often than before  
Was the treatment change more often a:  
 ï‚£ Step down (for example: lower dose/fewer drugs)  
 ï‚£ Step up (for example: higher dose/additional drugs)  
 ï‚£ Same level (for example: similar clas s/level of treatment)  
ï‚£ Less often than before  
 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144689] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 100 
 What features of AMAZEâ„¢ do you think could be improved?  
______________________________________________  
______________________________________________  
______________________________________________  
 
 
What barriers did you encounter in implementing AMAZEâ„¢ into your clinical practice?  
______________________________________________  
______________________________________________  
______________________________________________  
 
Do you have any other comments or s uggestion?  
______________________________________________  
______________________________________________  
______________________________________________  
 
  
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
$33(1',;- 3$7,(176$7,6)$&7,2148(67,211$,5(
364
3DUWLFLSDQW6DWLVIDFWLRQ4XHVWLRQQDLUH364

'HDU5HVHDUFK3DUWLFLSDQW7KDQN\RXIRUWDNLQJSDUWRIWKH$0$=(ÂŒ$ VWKPD5HVHDUFK6WXG\D W0DVVDFKXVHWWV*HQHUDO
+RVSLWDO0*+
$VSDUWRIWKHVWXG\SURFHGXUHSOHDVH FRPSOHWHWKHVXUYH\EHOR Z

,I\RXKDYHDQ\ TXHVWLRQVSOHDVHFRQWDFWWKH6WXG\7HDPDW  
7KDQN\RX

,QWKHWDEOHEHORZDUHVRPHWKLQ JVSHRSOHVD\DERXWPHGLFDOFDU H3OHDVHUHDGHDFKRQH
FDUHIXOO\NHHSLQJLQPLQGWKHPHG LFDOFDUH\RXDUHUHFHLYLQJQ RZ,I\RXKDYHQRWUHFHLYHG
FDUHUHFHQWO\WKLQNDERXWZKDW\R XZRXOGH[SHFWLI\RXQHHGHG FDUHWRGD\:HDUH
LQWHUHVWHGLQ\RXUIHHOLQJVJRRG DQGEDGDERXWWKHPHGLFDOFD UH\RXKDYHUHFHLYHG
CCI
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144690] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 102 
  

Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144691] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 103 
  
  

6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
$33(1',;.6,;0217+&+$575(9,(:&$6(5(3257
)250
CCI
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144692] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 105 
                         New Medication/ Continued, Same Dose/ Continued, Increased Dose/ Continued, Decrease Dose/ Discontinued/ Not Applicable  
 
ICS - Aerospan (flunisolide)  
ICS - Alvesco (ciclesonide)  
ICS - Arnuity  Ellipta (fluticasone  
furoate inhalation powder)  
ICS - Asmanex Twisthaler/HFA  
(mometasone furoate)  
ICS - Beclovent HFA  
(beclomethasone dipropi[INVESTIGATOR_16847])  
ICS - Flovent HFA/Disc  
(fluticasone propi[INVESTIGATOR_16847])  
ICS - Flunisolide  
ICS - Pulmicort  
Flexhaler/ Respules (budesonide)  
ICS - QVAR HFA/Redihaler  
(beclomethasone dipropi[INVESTIGATOR_16847])  
ICS - Triamcinolone Acetonide  
ICS - Vanceril HFA  
(beclomethasone dipropi[INVESTIGATOR_16847])  
ICS/LABA - Advair Diskus/HFA  
(fluticasone propi[INVESTIGATOR_825445])  
ICS/LABA - Airduo Respi[INVESTIGATOR_342407]  
(fluticasone propi[INVESTIGATOR_825445])  
ICS/LABA - Breo Ellipta  
(fluticasone furoate and  
vilanterol)  
ICS/LABA - 
IBCuSd/eLAsoBnAi d -e D/fuolremrao tHeFrAol  
(mometasone furoate and  
formoterol fumarate dihydrate)  
ICS/LABA - Symbicort  
(budesonide/formoterol  
fumarate dihydrate)  
ICS/LABA - Wixela Inhub  
(fluticasone propi[INVESTIGATOR_825445])  
LABA - Arcapta (Indacaterol)  
LABA - Arformoterol  
LABA - Brovana (arformoterol  
tartrate)  
LABA - Foradil (formoterol  
fumarate)  
LABA - Indacaterol  
LABA - Serevent (Salmeterol  
xinafoate)  
LABA - Striverdi (Oldaterol)  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144693] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 106 
 LAMA - Incruse Ellipta  
(Umeclidinium)  
LAMA - Spi[INVESTIGATOR_825447]/Handihaler (tiotropi[INVESTIGATOR_825448])  
LAMA - Tudorza/Aclidinium  
(aclidinium bromide)  
Triple Therapy (fixed dose  
combination) - Trelegy Ellipta  
(fluticasone furoate,  
umeclidinium, vilanterol)  
LTRA - Accolate (Zafirlukast)  
LTRA - Singulair (montelukast  
sodium)  
LTRA - Zyflo (zileuton)  
Theophylline Preparations - 
Elixophylline (Theophylline)  
Theophylline Preparations - 
Theo -24 (Theophylline)  
Theophylline Preparations - 
Theochron (Theophylline)  
Chronic Add -on Therapy  
(Macrolides) - Zithromax  
(Azithromycin)  
Chronic Add -on Therapy  
(Macrolides) - Biaxin  
(Clarithromycin)  
Chronic Add -on Therapy  
(Macrolides) - Erythromycin  
(Erythrocin)  
Biologics - Cinqair (reslizumab)  
Biologics - Dupi[INVESTIGATOR_12460] (dupi[INVESTIGATOR_12458])  
Biologics - Fasenra  
(benralizumab)  
Biologics - Nucala  
(Bmioelopgoilcizsu -m Xaobla)ir (omalizumab)  
Rescue Inhaler Use - Daily Use  
(SABA)  
Rescue Inhaler Use - SABA alone  
Rescue Inhaler Use - SABA+ICS  
Rescue Inhaler Use - LABA+ICS  
Rescue Inhaler Use - Nebulizer  
Rescue Inhaler Use - SAMA  
Other - Please specify  
Name [CONTACT_825480] D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144694] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 107 
 ASTHMA EXACERBATION HISTORY  
An asthma exacerbation is defined by a change in asthma control requiring a course of oral 
steroids (i.e., at least [ADDRESS_1144695]) and/or steroid injection 
and/or a hospi[INVESTIGATOR_825449] . 
Importantly , record only the highest utilization for each exacerbation, do not double 
count exacerbation epi[INVESTIGATOR_1841].  If an OCS course was due to a hospi[INVESTIGATOR_059] , do not record 
as OCS course but as the hospi[INVESTIGATOR_059]  
 
4. Number of times since  enrollment asthma symptoms required an emergency 
department or urgent care visit (but not an overnight stay in the hospi[INVESTIGATOR_307] ): 
 _____ ER/urgent care visits (with no overnight hospi[INVESTIGATOR_4408])  
 
5. Number of times since enrollment that there was a worsening in asthma symptoms that 
required a hospi[INVESTIGATOR_825450] 24 hours : ______ times admitted to hospi[INVESTIGATOR_307]  
 
6. Number of unplanned ambulatory clinic visits due to exacerbation in since enrollment : 
_____ unplanned visits   
 
7. How ma ny courses of oral corticosteroids (OCS) was the patient prescribed over the 
since enrollment for asthma exacerbations unrelated to emergency department, urgent 
care or, unplanned ambulatory clinic visits or hospi[INVESTIGATOR_18543] s? _______  
 
 
Investigator Final Confirmation  
 
Investigator/Coordinator Full Name  
 
[CONTACT_825481]/Coordinator Signature: _____________________________________  
 
Date:   ____________________  
  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144696] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 108 
 20. APPENDIX L. MGH WORKFLOW FOR IMPLEMENTATION OF 
DMP IN CLINICAL PRACTICE  
  Screening:  
~33 young adults (18 â€“35 yr) and up to 17 adults  (>=36 yr).   
 
Inclusion Criteria:   
-  >=18 yr with Dx of asthma  (with or 
without COPD).   
-  Own smartphone with compatible OS.   
-  Able to sufficiently use the AMAZE â„¢ 
patient App.   
-  Consenting to participate in the study 
procedures.    Exclusion Criteria:   
- No current diagnosis of asthma.  
-  Cognitive impairment, hearing 
difficulty, insufficient knowledge of 
English, or any medical condition 
interfering with  study participation.  
Enrollment:  
-  eConsent via REDCap.  
-  Download AMAZE â„¢ App, set up account, provided with a unique identifier.   
Baseline Visit:  
-  Patient to complete sociodemographic form.   
-  Staff will complete a clinical CRF  in REDCap . 
Patient to complete:   
- Daily log  
- ACTâ„¢ (every four weeks)  
- Patient User Experience Survey (months 1, 3, and 6 via email)   
- Patient Visit Experience Survey (after each in-person or telehealth clinic visit )   
- System Usability Scale  (months 1 and 6)  
- Patient Satisfaction Questionnaire -18   
- 12 patients for longitudinal interviews at months 1, 3, and 6;  
- 5 patients for one cross -sectional interview at months 2, 4, or 5 .  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144697] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 109 
   MGH staff to complete:   
- Clinical Case Report Form (initial visit)  
- Chart Review Case Report Form (month 6)   
- System Usability Scale (months 1 and 6)  
- Follow -up Process Interviews ( n=4, months 1, 3, and 6)  
- Post -study Survey     Study monitoring:   
- Nurse to monitor the patient 
dashboard twice a day  
- Physician to review the 
dashboard during every clinical 
visit 
Outcomes:   
Primary Outcome:  Feasibility, usability, perceived value, and potential benefits of the AMAZE â„¢ 
implemented i n clinical practice.   
 
Process Outcomes:  Evaluating the impact of AMAZE â„¢ on clinical practice, including duration of 
patient visits and services, as well as responses to survey items on changes to timing of 
scheduling visits, communication during the visit , and satisfaction with medical care received.  
Exploratory Clinical Outcomes: evaluate how AMAZETM impacts key clinical outcomes including 
exacerbations, HCRU, change in therapy, and exposure to COVID -19 
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
$33(1',;03$7,(1786(5(;3(5,(1&(6859(<
8VHU([SHULHQFH6XUYH\$0$=(ÂŒ$SS

'HDU5HVHDUFK3DUWLFLSDQW

7KDQN\RXIRUWDNLQJSDUWRIWKH$0$=(ÂŒ$VWKPD5HVHDUFK6WXG\D W0DVVDFKXVHWWV*HQHUDO+RVSLWDO
0*+

$VSDUWRIWKHVWXG\SURFHGXUHSOHDVHFRPSOHWHWKHVXUYH\EHOR Z

,I\RXKDYHDQ\TXHV WLRQVSOHDVHFRQWDFWWKH6WXG\7HDPDW 

7KDQN\RX
,QJHQHUDOKRZZRXOG\RXGHVFULEH \RXUDVWKPDLQWHUPVRIVHYH ULW\"
$0LOG
%0RGHUDWH
&6HYHUH
'2WKHU3OHDVHVSHFLI\BBBBBBBBBBB

$SSUR[LPDWHO\KRZPDQ\DVWKPDIODUH XSVDOVRFDOOHGH[DFHUEDW LRQVGLG\RXKDYHLQWKHODVW
GD\V"
BBBBBBBBRIIODUHXSV

:KRLV\RXUSULPDU\DVWKPDGRFWRUD W0DVVDFKXVHWWV*HQHUDO+RVS LWDO0*+"CCI
[COMPANY_003]
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
2WKHU3OHDVH6SHFLI\BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB

2YHUDOOKRZVDWLVILHGDUH \RXZLWK\RXUDVWKPDFDUHDW0*+"
9HU\8QVDWLVILHG
8QVDWLVILHG
1HXWUDO
6DWLVILHG
9HU\6DWLVILHG

,QGLFDWH\RXUOHYHORIDJU HHPHQWZLWKWKHIROORZLQJVWDWHPHQW 

,KDYHFRQWURORYHUP\DVWKPD
6WURQJO\$JUHH
$JUHH
1HLWKHU
'LVDJUHH
6WURQJO\GLVDJUHH

,XQGHUVWDQGP\DVWKPD
6WURQJO\DJUHH
$JUHH
1HLWKHUDJUHHQRUGLVDJUHH
'LVDJUHH
6WURQJO\GLVDJUHH

6LQFHWKHVWDUWRIWKHVWXG\XVHRIWKH$0$=(70DSSKHOSHGPHDYRLG(5RU8UJH QW&DUHFHQWHU
YLVLWVRUKRVSLWDOL]DWLRQV

$6WURQJO\DJUHH
%$JUHH
&1HLWKHUDJUHHQRUGLVDJUHH
''LVDJUHH
(6WURQJO\GLVDJUHH
)1RWDSSOLFDEOHÂ±,GLGQRWXVHWKHDSS

3OHDVHUDWHWKHIROORZLQJIHDWXUHVXVLQJDSRLQWUDWLQJZLWKEHLQJWKH EHVWSRVVLEOHVFRUH,I
\RXGRQRWXVHDJLYHQIHDWXUH\RXGRQRWKDYHWRUDWHLW

ORZHVWVFRUH



KLJKHVWVFRUH
'LGQRWXVHWKHIHDWXUH[COMPANY_003]
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB

'DLO\ORJZKHUH\RXWUDFNV\PSWRPVHWF
0HVVDJLQJZLWK0*+$VWKPDHGXFDWLRQDUWLFOHVYLGHRV$LUTXDOLW\0\3ODQOLVWRIPHGV	UHPLQGHUV7UHQGVGDLO\ORJVX[COMPANY_003]ULHVJUDSKV$SSRLQWPHQWVYLHZLQJDQGVFKHGXOLQJ&DUH7HDP5HTXHVW$VWKPD&RQW URO7HVWÂŒPRQWKO\TXHVWLRQVX UYH\

+RZIUHTXHQWO\GR\RXZDQWW RWUDFNWKHIROORZLQJIRU\RXUGRFW RU
6\PSWRPV 'DLO\:HHNO\0RQWKO\ 2WKHU3OHDVH6SHFLI\BBBBBBB
$VWKPDWULJJHUV 'DLO\:HHNO\0RQWKO\ 2WKHU3OHDVH6SHFLI\BBBBBBB
5HVFXHPHGLFDWLRQXVH 'DLO\:HHNO\0RQWKO\ 2WKHU3OHDVH6SHFLI\BBBBBBB
0DLQWHQDQFHPHGLFDWLRQXVH 'DLO\:HHNO\0RQWKO\ 2WKHU3OHDVH6SHFLI\BBBBBB
6WHURLGPHGLFDWLRQXVH 'DLO\:HHNO\0RQWKO\ 2WKHU3OHDVH6SHFLI\BBBBBBB
(58UJHQW&DUHYLVLWV 'DLO\:HHNO\0RQWKO\ 2WKHU3OHDVH6SHFLI\BBBBBBB
3HDNIORZ)(9 'DLO\:HHNO\0RQWKO\ 2WKHU3OHDVH6SHFLI\BBBBBBB

:KDWFRQFHUQVLIDQ\GR\RXKD YHDERXWWKH$0$=(
70DSS">6HOHFWDOOWKDWDSSO\@
'DWDSULYDF\FRQFHUQV,GRQRWILQGWKHDSSKHOSIXO,IRUJHWWRXVHLW7KHUHDUHWKLQJVPLVVLQJWKDW,ZDQWLQWKHDSS,WLVQRWIXQWRXVH,WLVQRWHDV\WRXVH2WKHUBBBBBBBBBBBBBBBBBBBBB>UDGLREXWWRQ@,GRQRWKDYHDQ\FRQFHUQV

2YHUDOOKRZVDWLVILHGDUH\RXZLWKWKH$0$=(70$SS"
9HU\8QVDWLVILHG
8QVDWLVILHG1HXWUDO6DWLVILHG
9HU\6DWLVILHG

:K\GR\RXIHHOWKDWZD \DERXWWKH$0$=(70$SS"
BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBB
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144698] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 113 
   
How likely are you to recommend the AMAZETM App to another patient at MGH who has 
asthma?  
Very Unlikely  
Unlikely  
Undecided  
Likely  
Very Likely  
 
Please share any additio nal feedback you have about the app (suggested topi[INVESTIGATOR_34631]):  
â€¢ What you like vs do not like about the app  
â€¢ What works well vs what does not  
â€¢ Any issues / bugs you have found in the app  
â€¢ Anything else you think we should know about the app  
 
 
  
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
$33(1',;16<67(086 $%,/,7<6&$/(686
$'0,1,67(5('$70217+6$1'3DWLHQWV 
6\VWHP8VDELOLW\6FDOH 6XUYH\$0$=(ÂŒ$SS 
'HDU5HVHDUFK3DUWLFLSDQW
7KDQN\RXIRUWDNLQJSDUWRIWKH$0$=(ÂŒ$ VWKPD5HVHDUFK6WXG\D W0DVVDFKXVHWWV*HQHUDO
+RVSLWDO0*+$VSDUWRIWKHVWXG\SURFHGXUHSOHDVH FRPSOHWHWKHVXUYH\EHOR Z

,I\RXKDYHDQ\TXHVWLRQVSOHDVH FRQWDFWWKH6WXG\7HDPDW 

7KDQN\RX
)RUHDFKRIWKHIROORZLQJVWDWHPH QWVPDUNRQHER[WKDWEHVWGH VFULEHV\RXUUHDFWLRQVWRWKH
$0$=(70$SSOLFDWLRQ$SS
 6WURQJO\
$JUHH$JUHH 1HXWUDO 'LVDJUHH 6WURQJO\
'LVDJUHH
,WKLQNWKDW,ZRXOGOLNHWRXVHWKLVDSS
IUHTXHQWO\Â…Â…Â… Â… Â…
,IRXQGWKHDSSXQQHFHVVDULO\FRPSOH[ Â…Â…Â… Â… Â…
,WKRXJKWWKHDSSZDVHDV\WRXVH Â…Â…Â… Â… Â…
,WKLQNWKDW,ZRXOGQHHGWKHVXSSRUWRID
WHFKQLFDOSHUVRQWREHDEOHWRXVHWKLV
DSSÂ…Â…Â… Â… Â…
,IRXQGWKHYDULRXVIXQFWLRQVLQWKLVDSS
ZHUHZHOOLQWHJUDWHGÂ…Â…Â… Â… Â…
,WKRXJKWWKHUHZDVWRRPXFK
LQFRQVLVWHQF\LQWKLVDSSÂ…Â…Â… Â… Â…
,ZRXOGLPDJLQHWKDWPRVWSHRSOHZRXOG
OHDUQWRXVHWKLVDSSYHU\TXLFNO\Â…Â…Â… Â… Â…
,IRXQGWKHDSSYHU\FXPEHUVRPHWRXVH Â…Â…Â… Â… Â…
,IHOWYHU\FRQILGHQWXVLQJWKHDSS Â…Â…Â… Â… Â…
,QHHGHGWROHDUQDORWRIWKLQJVEHIRUH,
FRXOGJHWJRLQJZLWKWKLVDSSÂ…Â…Â… Â… Â…

CCI
6WXG\3URWRFRO
6WXG\&RGH'5>(9$@9HUVLRQ
'DWH$XJXVW
6WXG\3URWRFRO)RUP
9HUVLRQ
)RUP'RF,'$='RF
3DUHQW'RF,'623/'06BB
$33(1',;16<67(086 $%,/,7<6&$/(686
$'0,1,67(5('$70217+6$1'0*+6WDII
6\VWHP8VDELOLW\6FDOH6XUYH\$ 0$=(ÂŒ$SSÂ±&OLQLFDO6WDII5HVH DUFK3DUWLFLSDQW

'HDU&OLQLFDO6WDII5HVHDUFK3DUWLFLSDQW7KDQN\RXIRUWDNLQJSDUWRIWKH$0$=(ÂŒ$ VWKPD5HVHDUFK6WXG\D W0DVVDFKXVHWWV*HQHUDO
+RVSLWDO0*+
$VSDUWRIWKHVWXG\SURFHGXUHSOHDVH FRPSOHWHWKHVXUYH\EHOR Z

,I\RXKDYHDQ\TXHVWLRQVSO HDVHFRQWDFWWKH6 WXG\7HDPDW  
7KDQN\RX
)RUHDFKRIWKHIROORZLQJVWDWHPH QWVPDUNRQHER[WKDWEHVWGH VFULEHV\RXUUHDFWLRQVWRWKH
$0$=(70FOLQLFLDQGDVKERDUG
 6WURQJO\
$JUHH$JUHH 1HXWUDO 'LVDJUHH 6WURQJO\
'LVDJUHH
,WKLQNWKDW,ZRXOGOLNHWRXVHWKLV
GDVKERDUGIUHTXHQWO\Â…Â…Â… Â… Â…
,IRXQGWKHGDVKERDUGXQQHFHVVDULO\
FRPSOH[Â…Â…Â… Â… Â…
,WKRXJKWWKHGDVKERDU GZDVHDV\WRXVH Â…Â…Â… Â… Â…
,WKLQNWKDW,ZRXOGQHHGWKHVXSSRUWRID
WHFKQLFDOSHUVRQWREHDEOHWRXVHWKLV
GDVKERDUGÂ…Â…Â… Â… Â…
,IRXQGWKHYDULRXVIXQFWLRQVLQWKLV
GDVKERDUGZHUHZHOOLQWHJUDWHGÂ…Â…Â… Â… Â…
,WKRXJKWWKHUHZDVWRRPXFK
LQFRQVLVWHQF\LQWKLVGDVKERDUGÂ…Â…Â… Â… Â…
,ZRXOGLPDJLQHWKDWPRVWSHRSOHZRXOG
OHDUQWRXVHWKLVGDVKERDUGYHU\TXLFNO\Â…Â…Â… Â… Â…
,IRXQGWKHGDVKERDUGYHU\FXPEHUVRPH
WRXVHÂ…Â…Â… Â… Â…
,IHOWYHU\FRQILGHQWXVLQJWKHGDVKERDUG Â…Â…Â… Â… Â…
,QHHGHGWROHDUQDORWRIWKLQJVEHIRUH,
FRXOGJHWJRLQJZLWKWKLVGDVKERDUGÂ…Â…Â… Â… Â…

CCI
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144699] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 116 
 24. APPENDIX O. FOLLOW -UP SEMI -STRUCTURED INTERVIEW 
GUIDES  
Longitudinal Follow -up Interview Guide [For months One, Three, and Six]  
Hello, my name [CONTACT_832] [interviewer name] and I am working with [MGH] and [COMPANY_008] to see how well the 
new asthma app is working for you. You previously consented to participate in this study regarding the 
asthma app and you have been randomly selected to participate in up to three interviews periodically 
through the duration of the study (roughly 1, 3, and 6 months after you enrolled in the study). During  each 
interview, we will ask for your feedback on the [MGH] asthma app that you have been using, including 
ease of use, suggestions for changes.  There are no right or wrong answers; weâ€™d like to hear your personal 
experience with the app.  
I would like to  have your permission to audio record this session. The recording will be used to help us 
improve the app and write a report about the things we talked about here today. The audio will be 
transcribed by a third -party vendor, TransPerfect, but any identifyi ng information you say during the 
interview will be removed from the transcript . It will be kept confidential and your name [CONTACT_825482]. If an adverse event (side effect) for an [COMPANY_008] product were to come up during 
the cour se of this interview, I am required to report that.  
Begin Recorder:  This is participant ID [Insert number here] for [month one/three/six] longitudinal follow -
up interview of study EVA -[ZIP_CODE].  Do I have your permission to record this session?  I want to co nfirm 
that you still consent to participate in the interview.  
Thank you for completing the asthma app so far.    
Introduction  
First, weâ€™ll be going over a brief introduction to your experience with medical apps and your smartphone.  
1. How long have you have  been using the asthma app?  
2. When you initially started the study, you had an [iPhone or Android]. Just to confirm, do you still have 
that phone?  
3. Do you use any medical health apps beside the asthma app?  
a. [If needed]: If yes, what do you use and what do y ou use it for?  
Asthma App â€“ App Use and Experience  
Now Iâ€™d like to ask you a few questions on your overall thoughts on the app and the notification/reminder 
system.  
1. Overall, what do you think of the app?  
a. In what ways is it easy to use?  
b. In what ways is it hard to use?   
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144700] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 117 
 2. [For month 1 interview only ]: What did you think about the app when you were first contact[CONTACT_426] 
[MGH]?  
a. Walk me through the process of finding, downloading, and using the app.  
b. Was there anything confusing or difficult for  downloading the app and gaining access to the 
features?  
3. Is there anything confusing about using the asthma app?  
a. [If yes]: What is confusing?  
4. Do you have any trouble accessing any of the features in the app?  
a. [If yes]: Tell me more about that.  What troubl e do you have?  
5. What notifications or reminders, if any, do you receive from the asthma app?  
a. Do you find the reminders helpful?  
i. Do you recall what time of day you set the reminders for? Why did you choose that time?  
ii. [Probe as needed]: Do you recall what y ou received a reminder for (i.e., medications, daily 
log, air quality alerts)?  
b. [If no]: Did you turn your notifications off? Would daily reminders have been helpful?  
6. How often did you use the app? What time of day did you use it?  
a. [If less than once a da y]: Why did you use it less than once a day? Is there anything missing that 
would have made you more likely to use the app every day?  
7. How, if at all, did you report issues/problems that you found in the app? ( Note to interviewer: there is 
an option for pa rticipants to report bugs/issues in the app. )  
Features of the App  
1. What features of the Asthma App (i.e., daily log, trends, messaging) do you use?  
Now Iâ€™d like to go through each of the features with you. Feel free to open your app while we go through 
the sections. [Interviewer to wait for participant to open app if needed.]  
a. Interviewer for each of the features go through the following probes:  
i. Do y ou use this feature in the app? If yes, how often do you use the app? If no, why do you not 
use this feature?  
ii. How helpful is the feature? Would you continue to use this feature to help monitor your 
asthma?  
iii. Is there anything confusing or unclear about thi s feature? What ideas do you have to make the 
feature better?  
iv. [For daily log only]: Have you ever had to change any of your answers for the daily log? If so, 
did you have any problems making changes?  
v. [For daily log only]: What did you think about the amou nt of time it took you to complete the 
daily log? Was it too long, too short, or enough time?  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144701] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 [ADDRESS_1144702] any problems with the font size on any of the screens?  
a. Would you change anything about the way the text or images appear on any of the screens?  
Using the App to Communicate with Doctor or During Visits  
Now Iâ€™d like to discuss how you used the app to communicate with your doctor via the messaging feature 
or during a doctorâ€™s visit.  
[Note to interviewer: the previous section probes on the messagin g feature so use these probes if not fully 
addressed to this point.]  
1. How do you typi[INVESTIGATOR_825451]?  
2. Did you use the messaging feature to send communication to your doctor?  
a. If yes, what things did you discuss wh ile messaging your doctor?  
i. Would you continue to use the messaging feature in the future? Why or why not?  
ii. How often did you send messages to your doctor through the app?  
iii. Which subject line did you typi[INVESTIGATOR_825452]? [Note to interviewer: if needed explain that 
there is a forced choice for the subject line.]  
b. If no, why did you not use the messaging feature?  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144703] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 119 
 3. We noticed you had a doctorâ€™s visit on [insert date]. Did you and your doctor discuss anything 
regarding the app during the visit?  
a. If yes, what was discussed? Did you open the app during your visit and show any specific log or 
trends?  
i. How did the app change the communication with your doctor during the visit compared to 
previous visits?  
b. If no, do you think discussing the app or any featu re of the app would have been helpful during 
your visit?  
Long -Term Use  
1. Would you consider using this app as a part of your long -term asthma care? Why or why not?  
a. If no, what would improve your experience with completing this app every day?   
2. What do you  hope to gain from the app? What do you think your doctor will gain from you using the 
app?  
3. Do you feel like using the app has helped you avoid ER or hospi[INVESTIGATOR_6042]? Why or why not?  
4. Are you likely to recommend this app to a person living with asthma? Wh y or why not?  
5. What other feedback would you like to give us on this app today?  
 
Thank you!  We are all done with the interview. Interviewer should confirm the participant still 
has a ClinCard and let them know the $[insert payment] will be uploaded within  24 hours of the 
interview.  
 
Cross -Sectional Patient Discussion Guide:  AMAZEâ„¢ Asthma App  
â— Purpose. Hi, my name [CONTACT_832] [________] and Iâ€™m a researcher with [COMPANY_008], a 
pharmaceutical company. We wanted to speak with you today to get your feedback on the 
AMAZEâ„¢ asthma app that you have been using.  We want to know what you think of the 
app so we can contin ue making this app better for people like you.  
â— Anonymity / Confidentiality.  The research is all confidential and anonymous and none 
of your data will be directly paired to you.  To keep things confidential, please never say 
your full name [CONTACT_825483], 
etc.  Weâ€™ll stick to first names only.  
â— Honest Feedback. Feel free to provide your honest feedback about the app today.  Donâ€™t 
be afraid to share negative feedback, if you have any.  I didnâ€™t persona lly create this so it 
wonâ€™t hurt my feelings.   
â— Adverse Events. Iâ€™m not here to sell or market you any drug, but, if you should mention 
you had an adverse reaction come up on an [COMPANY_008] drug, I am required for 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144704] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 120 
 compliance reasons to report any details of that event you experienced.   
â— Questions .  Do you have any questions for me before we get started?  
 
Patient Intro  
1. Tell me a little about yourself â€“ what keeps you busy?  
2. How long have you been living with asthma?  
a. How would you characterize it: mild, moderate, severe?  
3. What are some of the biggest challenges you face living with asthma?  
 
Phone Type + Health Apps  
1. What type of phone do you have? I.e., Apple, Android?  
2. How do you typi[INVESTIGATOR_825453]?  What apps do you use the most?  
3. Besides the asthma app, what kind of health apps/tools do you use or have you used in the 
past?  
a. Examples:  Think AppleHealth, Fit Bit, Clinician portal, Headspace, etc.  
4. Do you use MyChart?  If so, how?  
 
Experience with AMAZEâ„¢  
App Introduction   
1. How did you first learn about the asthma app?  
a. What was your reaction when you heard about it?  
b. Why do you think your clinician(s) wanted yo u to use the asthma app?  
c. What made you decide to join the asthma study?  
Onboarding  
2. Can you walk me through the process of finding and getting started with the app?  
a. Who, if anyone, helped you get started with the app?  i.e., caregiver, staff, doctor  
b. How easy / difficult was it for you to find the app?  How did you find it?  
c. How easy / difficult was it for you to create an account?  
d. What issues, if any, did you encounter with getting started with the app?  
i. I.e., finding it, downloading it, creati ng an account, etc.  
3. Is there anything that could have been done differently to make onboarding to the app 
easier for you?  
Overall  
1. How have you been using the app?  How often?  
2. Have you encountered any issues / problems with the app?  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144705] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 121 
 a. How did you resolve the issue, if at all?  
3. Overall, what do you think of the asthma app?  
a. What parts are most / least useful?   
4. Did it remind you of any other apps youâ€™ve used before?  
Specific Features  
[Explore use and satisfaction of the following app feat ures]  
Questions for below:  
  -Did you use [feature]?  
  -How useful/helpful or not is [feature]?  
  -Any issues / problems with [feature]?  
  -What could be done to make this [feature] better?  
Feature Set  
Daily Log  
Air Quality  
Appointments  
Asthma Control Test (ACT  
Education  
My Plan  
Trends  
Messaging  
Notifications  
 
[Additional questions to probe on when exploring a given feature]  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144706] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 122 
 1. Daily log  
a. How often do you typi[INVESTIGATOR_825454]?  
i. What was your longest log streak?  
b. What time of day do you generally fill out the log?  Why that time?  
c. Are there any questions in the daily log that are confusing?  That do not apply to 
you?  
i. Do you own a peak flow meter?  Ability to record FEV1?  
d. Were the symptoms you were experiencing always reflected in the list of symptom 
options?  
i. What about triggers?  
e. To what extent did the medication question make sense?  Is â€˜Quick -relief / as -
neededâ€™ a familiar term?  
f. How helpful was the review screen?  
g. How often did you go back and add a log for days that you missed?  
h. How often did you go back in and edit logs?  
i. How,  if at all, do you know that a clinician is looking at your log data?  
j. Do you have any thoughts on how we can make filling out the log easier for you?  
2. Air Quality  
a. How important is air quality to track for you?   
b. Is this something you tracked prior to the ap p? 
c. How else did you use this feature i.e., did you use it to track allergens like pollen, 
ragweed, etc.?  
i. If yes, how helpful?  If no, why not?  
3. Appointments  
a. How accurate was the information reflected in the appointments card?  Anything 
unusual?   
b. How many  appointment reminders did you receive?  
c. Did you use the link to schedule additional appointments?  Why/why not?  
4. Asthma Control Test (ACT)  
a. How was this different from the daily log for you?  
b. How easy / difficult were the questions?  
c. Have you ever taken thi s questionnaire before?  
d. Why do you think your clinicians wanted you to answer these questions?  
5. Education  
a. Which articles did you explore if any?  
i. Asthma EDU?  Depression EDU?  
b. What education is missing that would be important to have?  
c. What type of media format do you prefer:  video, articles, podcasts, etc.?  
6. My Plan  
a. How helpful was it to have your list of medications available?  How did you use it?  
i. How accurate was the list o f medications?  How accurate were the images 
of your medications?  
ii. Was there anything confusing about the list?  
b. Did you use the medication reminder feature?  If so, how helpful was that?  
7. Trends  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144707] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 123 
 a. How did you use Trends?   
i. To what extent did you use Trends in your appointment(s) with your 
doctor?  
ii. Which view (daily, weekly) did you use the most?  
b. What do you think is the purpose of Trends?  
c. To what extent is this the type of information you are interested in seeing?  
d. How easy/difficult were the graphs to unde rstand and interpret?   
e. Did you use the â€˜share with caregiverâ€™ feature?  If so, who did you share with and 
why?  
8. Messaging  
a. What types of messages did you send to your clinician?  
i. Which subject line did you most commonly select?  
b. What was the response time l ike? 
c. How would you normally get in touch with your clinician before you had this app?  
9. Notifications  
a. What types of notifications did you receive from the app?  
b. How helpful were those notifications?  
c. Did you turn on/off any notifications? What did you think of the frequency?  
 
Bugs / Reporting  
1. Have you encountered any bugs in the app?  
a. [if yes] were you able to report the bug?  
2. Did you have to contact [CONTACT_825477]?   
a. If so, how helpful were they?   
b. Were they able to resolve the issue you had?  
 
Appointments with Doctor  
1. Have you had any appointments with your doctor since you started using the app?  
a. If yes, how if at all was that appointment different than what youâ€™re used to?  
b. How if at all did  they talk about the data that you put in the app?   
c. At any point during the appointment, did you pull up your app to show them 
anything you had recorded?  
 
Value  
1. What have you gained, if anything, from using this app?  
2. If you had a magic wand, what would you change about this app?  
3. On a scale of 1 to 5 (1=not  at all; 5=extremely), how likely would you be to recommend 
this app to someone else living with asthma?  
a. Why a [#]?  
b. [if less than 5] What would bring your score closer to a 5?  
What else do you think the team should know about the app that we havenâ€™t alrea dy discussed 
here today?  
  
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144708] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 124 
 25. APPENDIX P. RECRUITMENT TRACKING LOG  
RECRUITMENT TRACKING LOG (EVA -[ZIP_CODE] ): SITE [XXX]  
Please send the Recruitment Tracking Log to Evidera via SharePoint  
Participant 
ID BI Linked ID  Patient 
Age Patient 
Sex Recruitment Quotas  Phone Type (Operation 
System)  Outcome  Reason for 
Ineligible  
   ï¸ Male  
â‘ Female  â‘ New in practice (< 3 
months) but uncontrolled  
â‘ â‰¥ one exacerbation  in 
past 12 months  
â‘ Young adult  
â‘ Adult  â‘ iOS ( iOS 13 and iPhone 8 
or newer ) 
â‘ Android ( OS 8.0 or newer ) 
â‘ Other  
 ï¸ Eligible  
â‘ Ineligible  
â‘ Declined   
   â‘ Male  
â‘ Female  â‘ New in practice (< 3 
months) but uncontrolled  
â‘ â‰¥ one exacerbation in 
past 12 months  
â‘ Young adult  
â‘ Adult   â‘ iOS (iOS 13 and iPhone 8 
or newer)  
â‘ Android (OS 8.0 or newer)  
â‘ Other  
 â‘ Eligible  
â‘ Ineligible  
â‘ Declined   
   â‘ Male  
â‘ Female  â‘ New in practice (< 3 
months) but uncontrolled  
â‘ â‰¥ one exacerbation in 
past 12 months  
â‘ Young adult  
â‘ Adult   â‘ iOS (iOS 13 and iPhone 8 
or newer)  
â‘ Android (OS 8.0 or newer)  
â‘ Other  
 â‘ Eligible  
â‘ Ineligible  
â‘ Declined   
   â‘ Male  
â‘ Female  â‘ New in practice (< 3 
months) but uncontrolled  
â‘ â‰¥ one exacerbation in 
past 12 months  â‘ iOS (iOS 13 and iPhone 8 
or newer)  
â‘ Android (OS 8.0 or newer)  
â‘ Other  â‘ Eligible  
â‘ Ineligible  
â‘ Declined   
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144709] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 125 
 â‘ Young adult  
â‘ Adult    
 
Study Protocol  
Study Code D2287R00166 [EVA -[ZIP_CODE]]  
Version 7.[ADDRESS_1144710] 10 , 2021  
Study Protocol Form  
Version 7.4 
Form Doc ID: AZDoc0059948  
Parent Doc ID: SOP LDMS_001_00164328 126 
 26. SIGNATURES  
ASTRAZENECA SIGNATURE(S)  
 
 
AMAZE Asthma Implementation clinical pi[INVESTIGATOR_16116] - MGH  
 
 
This Interventional Study Protocol has been subjected to an internal [COMPANY_008] review.  
I agree to the terms of this Study protocol.  
[COMPANY_008] representative  
 <<Name, title>>  
 
<<Email address and telephone number>>  
 Date  
(Day Month Year)  
[COMPANY_008] representative    
 <<Name, title>>  
 
<<Email address and telephone number>>  Date  
(Day Month Year)  
 
This document contains confidential information, which should not be copi[INVESTIGATOR_530], referred to, 
released or published without written approval from [COMPANY_008].  Investigators are 
cautioned that the information in this protocol may be subject to change and revision.  
 
 
 